¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/1/22 ¤U¤È 01:59:24
²Ä 5083 ½g¦^À³
|
§Ú¬Oı±oª©±ÁÙ¦nªü ·|¨Ó¬Ýªº¤j³¡¤À³£¬O¦Ñ·à¤Í¤F ·à¤lºÞ²z°ª¼h¦Û¤v¦h¥[ªo¹ïªÑ»ù¤~¦³À°§U ¬O»¡³ÌªñÁöµM¤@ª½¶^¦ý¤]¤£¬O¥u¦³·à¤l³o¼Ë ¬üªÑ¾ãÓ¤p«¬ªÑpennyªÑ³£Ë¤@¤ù |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¯T10148959 |
µoªí®É¶¡:2022/1/22 ¤U¤È 01:08:51
²Ä 5082 ½g¦^À³
|
¥xÁÞ©Ò¨¥¬Æ¬O ¬O´«ª©¥DÁÙ¬O¥t¶}¥Lª©§¡¥i ·PÁª©¤W©Ò¦³¤£§[¤À¨Éªº¤j¤j |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/1/22 ¤W¤È 10:59:55
²Ä 5081 ½g¦^À³
|
To:¥xÁÞ¤j
Y¸gÀçªÌªº§@¬°¯à¨Ï±o¦Ñ·àªºª÷¿Ä¥«³õ»ùÈ´£¤É¡A¼ÐÃD¦ÛµM·|¤£¦P³á~~~²{¶¥¬q¦Ñ·à¥u¦³³o¼Ëªºªí²{¡A©Ò¥H§ÚÓ¤H¬Ýªk¥u¯à¦³³o¼Ëªº¼ÐÃD~~~µM³o¥¥x¬O¦hªÅ³£¯àºZ½ÍªºªÅ¶¡¡A§Æ±æ¤j®a³£¯àµoªí·N¨£¡A¨Ñ¤j®a°Ñ¦Ò¡F¦Ü©óª©¥Dªº°ÝÃD¡A¦]¤Ñ©R¤j¦b¥»ª©¤]°^Äm³\¦h¡A¦b¨ä¥L¦a¤è¥ç¤]¦³«Ü¦hª©nªá¤ß¤O¡A³o¼Ë¬O§_¤Ó³Â·Ð¤H®a ? ¦pªG´«ª©¥D¯àÅý¤j®a±o¨ì¦Ñ·à§ó¦nªºªÑ»ù¨º§Ú«Ü¼Ö·N¡A¦ýY¥u¬O¬°¤F¬Ý°_¨Ó¹ï¦Ñ·àªº¸gÀçªÌµ½·N¡A¨ºªø§ëªº¦Ñ·à¤Í´N¤Ó¥i¼¦¤F~~~
Aslan Pharmaceuticals KOL Webinar-1/20±M®a¤ÀªR¤ÎºtÁ¿³sµ²¦p¤U(»Ýµn¤J¤~¯àÆ[¬Ý) lifesci.rampard.com/WebcastingAppv5/Events/Registration/registration.jsp?Y2lk=MTYxMA==&Y2lk=MTYxMA%3D%3D
¥H¤W¥pÂZ~~~§Æ±æ¦Ñ·à¯àªê¦~·à§qªÑ»ù¤j¤Wº¦ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/1/22 ¤W¤È 10:20:40
²Ä 5080 ½g¦^À³
|
©t¨àÃĤj ¤Ñ©R¤j ¨È·à±d¥Ø«e¦³¬ãµo¥«³õ«Ü¤jªº003(¼ìºÅ©Êµ²¸zª¢ÄY IBD) »P 004 ²§¦ì©Ê¥Ö½§ª¢, ¥i¬Oª©±¼ÐÃD¦r¥u´£004 , ¤S·Q¤½¥q²£«~003 004 ¯à¬ãµo¦¨¥\³Q¨ÖÁÊ ,¤Sn«Øij´«±Mªø¬O¨ÖÁʪºCEO , ¥Dª©¤å ¤£¤Íµ½ ·Pı¤£¬O«Ü¦n «Øij©t¨àÃĤj ¥Ñ¤Ñ©R¤j±µª©¥D , ¥²³º¤Ñ©R¤j¹ï003 004 ¤ñ¸û¤F¸Ñ «·s×¥¿¥Dª©¤å, ¤£ª¾¨àÃĤj ¤Ñ©R¤j»P¤j®a·N¨£¦p¦ó ? ·s¦~·s®ð¶H , ¬Ý¬ÝªÑ»ù·|¤£·|²Å¦XÀ³¦³ªº»ùÈ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2022/1/22 ¤W¤È 09:01:37
²Ä 5079 ½g¦^À³
|
ec.ltn.com.tw/article/breakingnews/2723576
³o¬O2019¦~ªº·s»D¡A¸Ì±¦³´£¨ì¡ABioGenetics³o¶¡¤½¥q·|ÃÙ§U003ªº¶}µo¶O¥Î¡A¤£ª¾¹D«áÄò¦p¦ó?
¸`¿ý¤@¬q¦p¤U:
·sÃĶ}µo¤½¥q¨È·à±d-KY ¡]6497¡^¬Q«Å¥¬¡A±N¸Ó¤½¥q¬ãµoªº·sÃÄASLAN003±ÂÅv«nÁúª¾¦WÂåÀø²£«~¤½¥qBioGenetics¡ABioGenetics±N¤ä¥I¨È·à±d-KY 100¸U¬ü¤¸¤§Ã±¬ùª÷©M³Ì°ª¹F800¸U¬ü¤¸¤§¾P°â»P¬ãµo¨½µ{ª÷¡C¦¹¥~¡A¨È·à±d-KY±N¥i¨Ì¾P°â²bÃB¤À¼h¦¬¨ú¤@¦rÀY°ª¦ì¼Æ¦Ü¤G¦rÀY¤¤¦ì¼Æ¤§Âù¦ì¼Æ¤ñ¨ÒÅv§Qª÷¡CBioGenetics±N¸ê§UASLAN003«æ©Ê°©Åè©Ê¥Õ¦å¯fÁ{§É¸ÕÅ礧¥þ²y¬ãµo¶O¥Î¡A¨Ã±Nt³d¨ú±oASLAN003¦b«nÁú«e´Á©M©Ò¦³«áÄò¬ÛÃö¤§ªk³W®Öã¡C
¤£½T©w³oÓ¦³¨S¦³¼g¦bÂù¤èñqªº¦X¬ù¤W±¡A¦³ªº¸ÜÀ³¸Ó¥i¥HÀò±o¤£¤ÖÃÙ§U¶O¥Î¡AÁÙ¬O¦]¬°001¥¢±Ñ¤F¡A³o¥ó¨Æ±¡´N¤£¤F¤F¤§¤F¡A¤£ª¾¹DÁÙ¦³¤H¦bfollow³o¥ó¨Æ±¡¹À¡ABioGenetics¤§«e¤]¦³¸ò¨È·à±dñq001ªº±ÂÅv¡C
¤£ª¾¹D¤Ñ©R¤jÁÙ¦³¦bfollow 003ªº¬ÛÃö¸ê°T¹À¡A¬Ý¤½¥q³ÌªñªºÂ²³ø³£¨S´£¨ì³o¥ó¨Æ±¡¤F¡C
Thanks, |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/21 ¤W¤È 07:34:15
²Ä 5078 ½g¦^À³
|
«Å¥¬ASLAN004(Eblasakimab) 2b ADÁ{§É¿z¿ï²Ä¤@¦ì±wªÌ¡C
ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis ASLAN PHARMACEUTICALS LIMITED Fri, January 21, 2022, 5:05 AM¡P6 min read In this article: The TRials with EblasaKimab in Atopic Dermatitis (TREK-AD) study will evaluate the efficacy and safety of ASLAN004, now known as eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor
This dose-ranging study is expected to enroll approximately 300 patients and will evaluate 4 dose regimens
Topline results are expected in 1H 2023
MENLO PARK, Calif. and SINGAPORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has screened the first patient in its Phase 2b dose-ranging clinical study of eblasakimab in adults with moderate-to-severe atopic dermatitis (AD). Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to provide a differentiated treatment option for patients. ASLAN expects to report topline findings from the 16-week treatment period in the first half of 2023. ASLAN Pharmaceuticals ±Ò°Ê ASLAN004 (Eblasakimab) ¦b¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢¤¤ªº 2b ´Á¬ã¨s ¨È´µÄõÃÄ·~¦³¤½¥q 2022 ¦~ 1 ¤ë 21 ¤é¬P´Á¤ 5:05 AM¡P6 ¤ÀÄÁ¾\Ū ¦b³o½g¤å³¹¤¤¡G EblasaKimab ¦b¯SÀ³©Ê¥Öª¢ (TREK-AD) ¬ã¨s¤¤ªº¸ÕÅç±Nµû¦ô ASLAN004¡]²{ºÙ¬° eblasakimab¡^ªºÀø®Ä©M¦w¥þ©Ê¡A³o¬O¤@ºØ¼ç¦bªº°w¹ï IL-13 ¨üÅ骺¤@¬y§ÜÅé
³o¶µ¾¯¶q½d³ò¬ã¨s¹wp±N©Û¶Ò¬ù 300 ¦W±wªÌ¡A¨Ã±Nµû¦ô 4 ºØ¾¯¶q¤è®×
¹wp 2023 ¦~¤W¥b¦~·~ÁZ
¥[§QºÖ¥§¨È¦{ªù¬¥©¬§J©M·s¥[©Y¡A2022 ¦~ 1 ¤ë 20 ¤é (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN) ¬O¤@®aÁ{§É¶¥¬q¡B¥H§K¬Ì¾Ç¬°«ÂIªº¥Íª«»sÃĤ½¥q¡A¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A
¤µ¤Ñ«Å¥¬¡G¥¦¤w¸g¦b¦¨¤H¤¤««×¯SÀ³©Ê¥Öª¢¡] AD ¡^ªº eblasakimab 2b ´Á¾¯¶q½d³òÁ{§É¬ã¨s¤¤¿z¿ï¤F²Ä¤@¦ì±wªÌ¡C
Eblasakimab ¬O¤@ºØ¼ç¦bªº¤@¬yªº¹v¦V IL-13 ¨üÅ骺³æ§J¶©§ÜÅé¡A¦³¥i¯à¬°±wªÌ´£¨Ñ®t²§¤ÆªºªvÀø¿ï¾Ü¡C ASLAN ¹wp±N¦b 2023 ¦~¤W¥b¦~³ø§i 16 ©PªvÀø´Áªº¥Dnµ²ªG¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/21 ¤W¤È 07:17:18
²Ä 5077 ½g¦^À³
|
Eblasakimab=ASLAN004ªº¾Ç¦W
Eblasakimab 2b Á{§É®×¦W:TREK-AD
The TRials with EblasaKimab in Atopic Dermatitis (TREK-AD) study will evaluate the efficacy and safety of ASLAN004, now known as eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor
This dose-ranging study is expected to enroll approximately 300 patients and will evaluate 4 dose regimens
Topline results are expected in 1H 2023 2023¦~¤W¥b¦~¸Ñª¼ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/1/21 ¤W¤È 06:42:09
²Ä 5076 ½g¦^À³
|
finance.yahoo.com/news/aslan-pharmaceuticals-initiates-phase-2b-210500276.html#aoh=16427136910308&referrer=https%3A%2F%2Fwww.google.com&_tf=%E4%BE%86%E6%BA%90%EF%BC%9A%251%24s&share=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Faslan-pharmaceuticals-initiates-phase-2b-210500276.html |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/20 ¤U¤È 08:55:48
²Ä 5075 ½g¦^À³
|
CIBINQO¡@^¤å¥é³æ
¡X¡X¡X¦³ºë±m¤º®e¡X¡X¡X¡X
cdn.pfizer.com/pfizercom/USPI_Med_Guide_CIBINQO_Abrocitinib_tablet.pdf
³B¤è«H®§nÂI ³o¨Ç«GÂI¤£¥]¬A¨Ï¥Î©Ò»Ýªº©Ò¦³«H®§
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CIBINQO safely and effectively. See full prescribing information for CIBINQO. CIBINQOTM (abrocitinib) tablets, for oral use Initial U.S. Approval: 2022 ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X -----------------------DOSAGE AND ADMINISTRATION----------------------- For recommended testing, evaluations and procedures prior to CIBINQO initiation, see Full Prescribing Information. (2.1) Recommended dosage is 100 mg orally once daily. (2.2) 200 mg orally once daily is recommended for those patients who are not responding to 100 mg once daily. (2.2) Moderate renal impairment: 50 mg once daily or 100 mg once daily for those patients who are not responding to 50 mg once daily. (2.3) CYP2C19 poor metabolizer: 50 mg once daily or 100 mg once daily for those patients who are not responding to 50 mg once daily. (2.4) For dosage modifications for certain adverse reactions, see Full Prescribing Information. (2.6
- - - - - - - - - - - -¾¯¶q©Mµ¹ÃÄ - - - - - - - - - - - - ¹ï©ó CIBINQO ¤§«eªº±ÀÂË´ú¸Õ¡Bµû¦ô©Mµ{§Ç ±Ò°Ê¡A½Ð°Ñ¾\§¹¾ãªº³B¤è«H®§¡C (2.1)
±ÀÂ˾¯¶q¬°¨C¤Ñ¤@¦¸¤fªA 100 ²@§J¡C (2.2)
±ÀÂ˨C¤Ñ¤@¦¸ 100 ²@§J没ÅTÀ³ªº±wªÌ¨C¤Ñ¤fªA 200 ²@§J ¡C (2.2)
¤¤«×µÇ¥\¯à¤£¥þ¡G¨C¤Ñ¤@¦¸ 50 ²@§J©Î¨C¤Ñ¤@¦¸ 100 ²@§J ¨º¨Ç¹ï¨C¤Ñ¤@¦¸ 50 ²@§J¨S¦³¤ÏÀ³ªº±wªÌ¡C (2.3)
CYP2C19 §C¥NÁª̡G¨C¤Ñ¤@¦¸ 50 ²@§J©Î¨C¤Ñ¤@¦¸ 100 ²@§J ¨º¨Ç¹ï¨C¤Ñ¤@¦¸ 50 ²@§J¨S¦³¤ÏÀ³ªº±wªÌ¡C (2.4) ¹ï©ó¬Y¨Ç¤£¨}¤ÏÀ³ªº¾¯¶q½Õ¾ã¡A½Ð°Ñ¾\§¹¾ã³B¤è «H®§¡C (2.6
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS See full prescribing information for complete boxed warning. Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Discontinue treatment with CIBINQO if serious or opportunistic infection occurs. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative latent TB test. (5.1) Higher rate of all-cause mortality, including sudden cardiovascular death, with another JAK inhibitor vs. TNF blockers in rheumatoid arthritis (RA) patients. CIBINQO is not approved for use in RA patients. (5.2) Malignancies have occurred with CIBINQO. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients. (5.3) MACE has occurred with CIBINQO. Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients. (5.4) Thrombosis has occurred with CIBINQO. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers. (5.5)
CIBINQO ¦w¥þ¦³®Ä¡C¬d¬Ý§¹¾ãªº³B¤è«H®§ ¦è»«ªG¡C CIBINQOTM¡]abrocitinib¡^¤ù¾¯¡A¥Î©ó¤fªA ¬ü°êº¦¸§åã¡G2022
ĵ§i¡GÄY«·P¬V¡B¦º¤`²v¡B ´c©Ê¸~½F¡A¥Dn¤£¨}¤ß¦åºÞ ¨Æ¥ó¡]MACE¡^©M¦å®ê§Î¦¨
¦³Ãö§¹¾ãªº¶Â®Øĵ§i¡A½Ð°Ñ¾\§¹¾ãªº³B¤è«H®§¡C
ÄY«²Óµß¡B¯uµß¡B¯f¬r©M¾÷·|¥D¸qªº·ÀI¼W¥[ ¾ÉP¦í°|©Î¦º¤`ªº·P¬V¡A¥]¬A µ²®Ö¯f¡]TB¡^¡C¦pªG¥X²{¥H¤U±¡ªp¡A½Ð°±¤î¨Ï¥Î CIBINQO ªvÀø µo¥ÍÄY«©Î¾÷·|©Ê·P¬V¡C´ú¸Õ¼ç¥ñ©Êµ²®Ö¯f ªvÀø«e©MªvÀø´Á¶¡¡F¨Ï¥Î«eªvÀø¼ç¥ñ©Êµ²®Ö¯f¡CºÊµø¾¹ ªvÀø´Á¶¡©Ò¦³¬¡°Ê©Êµ²®Ö¯f±wªÌ¡A§Y¨Ï¬O±w¦³¬¡°Ê©Êµ²®Ö¯fªº±wªÌ ªì©l³±©Ê¼ç¥ñ©Êµ²®Ö¯f¸ÕÅç¡C (5.1)
§ó°ªªº¥þ¦]¦º¤`²v¡A¥]¬AÖ`¦º ¤ß¦åºÞ¦º¤`¡A¥t¤@ºØ JAK §í»s¾¯¹ï¤ñ TNF Ãþ·ÀãÃö¸`ª¢¡]RA¡^±wªÌªºªýº¢¾¯¡C CIBINQO ¤£¬O §åã¥Î©óRA±wªÌ¡C (5.2)
CIBINQO µo¥Í¤F´c©Ê¸~½F¡C§ó°ªªº¤ñ²v ²O¤Ú½F©MªÍÀù»P¥t¤@ºØ JAK §í»s¾¯¹ï¤ñ Ãþ·ÀãÃö¸`ª¢±wªÌªº TNF ªýº¢¾¯¡C (5.3)
CIBINQO µo¥Í¤F MACE¡C¸û°ªªº MACE µo¥Í²v ¡]©w¸q¬°¤ß¦åºÞ¦º¤`¡B¤ß¦Ù±ð¶ë©M ¤¤·¡^»P¥t¤@ºØ JAK §í»s¾¯¹ï¤ñ RA ¤¤ªº TNF ªýº¢¾¯ @¤ß¡C (5.4)
CIBINQO µo¥Í¦å®ê§Î¦¨¡Cµo¯f²v¼W¥[ ªÍ®ê¶ë¡BÀR¯ß©M°Ê¯ß¦å®ê§Î¦¨ ¥t¤@ºØ JAK §í»s¾¯»P TNF ªýº¢¾¯¡C (5.5)
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X JADE MONO-¢°
¡G IGA ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 24%*¡B44%** ©M 8% EASI-75 ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 40%**¡B62%** ©M 12%
JADE MONO-2 IGA ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 28%**¡B38%** ©M 9% EASI-75 ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 44%**¡B61%** ©M 10%
Table 10. Efficacy Results of CIBINQO with Concomitant Topical Corticosteroids at Week 12 in Subjects with Moderate-to-Severe AD (Trial-AD-3)
CIBINQO¡Ï¢â¢Ñ¢á¡]¥~¥ÎÃþ©T¾J³n»I) IGA ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 36%**¡B47%** ©M 14% EASI-75 ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 58%**¡B68%** ©M 27%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2022/1/20 ¤W¤È 07:40:59
²Ä 5074 ½g¦^À³
|
ÁÂÁ¤ѩR¤j¤À¨É¬Ýªk¡A ³oÃĪº¦n³B¬O¤fªA¡A°Æ°µ¥Î¬O¯Ê奌¡A ³o¼Ë¦h°Æ°µ¥Î¡A¯f¤HÀ³¸Ó·|¦Ò¼{¤@¤U¬O¤£¬OnÀu¥ý¨Ï¥Î. ¨Ï¥ÎÀ³¸Ó¦³§½©Ê¡C
¥t¥~¡A§Ú¤]ªY½à «Ó°¶¤j ªºÁŹF and ¬Ýªk¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/20 ¤W¤È 06:17:44
²Ä 5073 ½g¦^À³
|
DHL ¤j¡A
CIBINQO
1¡A100mg °w¹ï¤¤-««× AD ¤@½uÃÄ
¬D¾Ô: A.Àø®Ä: 100mg/¤é Àø®Ä¡A ¤ñdupilumab ®t¡A ¥h°£¹ï·Ó组¼vÅT¡A¶È约dupikumab70%-80%
B.«¤j°Æ§@¥Î: ¦º¤`·ÀI:±wRA(Ãþ·ÀãÃö结ª¢)¸T¥Î ´c©Ê¸~½F Àù¯g ¦å®ê
Ó¤H§PÂ_:BININQO ,¦b¤@½u¥«³õ¤ñ¸ûµL§l¤Þ¤O¡C
2.200mg °w¹ï¤¤-««× AD ¤G½uÃÄ
¬D¾Ô 100mg.µL¤ÏÀ³¡A«á¤~¯à¥Î200mg
Y100mg¡A ¥Îªº¤H¤£¦h¡A则200mg¥çÃø¦³¦n销°â 3.Áo©úªº½÷·ç¥i¯àµ¦²¤ À³°µ¥t¤@ÓÁ{§É¡A©Û¶Ò¯u¥¿dupilumabµL¤ÏÀ³ªÌ¡A ª½±µ¥Î200mgªvÀø¡A¥h¦û领3¦¨ªº¤G½u¥«Ô·
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K CIBINQO ³Q§å㪺±ÀÂ˾¯¶q¬° 100 mg ©M 200 mg¡A
200 mg ¾¯¶q³Q±ÀÂ˥Ωó¹ï 100 mg ¾¯¶q¨S¦³¤ÏÀ³ªº±wªÌ¡C
¦¹¥~¡A50 mg ¾¯¶q³Q§åã¥Î©óªvÀø¤¤«×¦Ü««× AD¡A¯S§O¬O¦b¤¤«×µÇ¥\¯à¤£¥þ¡]µÇ°IºÜ¡^±wªÌ¡B
¬Y¨Ç±µ¨ü²ÓM¦â¯À P450 (CYP) 2C19 §í»s¾¯ªvÀøªº±wªÌ¡A©Î¤wª¾©ÎºÃ¦ü¬O CYP2C19 ªº®z¥NÁª̡C¹ï©ó¤¤«×µÇ¥\¯à¤£¥þªº±wªÌ¡A¹ï¨C¤Ñ¤@¦¸ 50 ²@§J¨S¦³¤ÏÀ³ªº±wªÌ¡A¤]¥i¥H¶}¥X¨C¤Ñ¤@¦¸ 100 ²@§Jªº³B¤è¡C
¡K¡K¡K¡K¡K¡K¡K
³æÁn¹D-1¡G IGA ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 24%*¡B44%** ©M 8% EASI-75 ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 40%**¡B62%** ©M 12% JADE MONO-2 IGA ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 28%**¡B38%** ©M 9% EASI-75 ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 44%**¡B61%** ©M 10% ¥É¥Û¤ñ¸û IGA ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 36%**¡B47%** ©M 14% EASI-75 ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 58%**¡B68%** ©M 27% ¦w¥þ©ÊÁÙ³q¹L¤@¶µÀH¾÷¾¯¶q½d³ò¸ÕÅç©M¤@¶µªø´Á¡B¶}©ñ¼ÐÅÒ¡BÂX®i¸ÕÅç¡]JADE EXTEND¡^¶i¦æ¤Fµû¦ô¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/19 ¤U¤È 11:11:17
²Ä 5072 ½g¦^À³
|
www-pfizer-com.translate.goog/news/press-release/press-release-detail/us-fda-approves-pfizers-cibinqor-abrocitinib-adults?_x_tr_sl=en&_x_tr_tl=zh-TW&_x_tr_hl=zh-TW&_x_tr_pto=sc
¥ý¥Î100mgµL®ÄªÌ¡A¦A¥Î200mg¤@¤@¤@¤@FDA«Øij
100mgÀø®Ä«Ü¤£«ç»ò¼Ë¡C
¤@¤j°ï«¤j¥ÎÃÄĵ§i¡C
¤@¤@¤@¤@¤K¤@¤@¤@¤@Æ¿ ¬ü°ê FDA §åã½÷·çªº CIBINQO®¡]abrocitinib¡^¥Î©ó¦¨¤H¤¤««×¯SÀ³©Ê¥Öª¢ 2022 ¦~ 1 ¤ë 14 ¤é¬P´Á¤ - ¤U¤È 3:30 CIBINQO ¬O¤@ºØ¨C¤é¤@¦¸ªº¤fªAªvÀøÃĪ«¡A¸gÃÒ¹ê¥i¦³®Ä½w¸Ñ¥Ø«e©|¥¼½w¸Ñ¯gª¬ªº¦¨¦~¤Hªº¯gª¬
¯Ã¬ù--(BUSINESS WIRE)--(¬ü°ê°Ó·~¸ê°T)--½÷·ç¤½¥q (NYSE: PFE) ¤µ¤Ñ«Å¥¬¡A¬ü°ê (US) ¹«~ÃÄ«~ºÊ·þºÞ²z§½ (FDA) §åã¤F CIBINQO ® (abrocitinib)¡A³o¬O¤@ºØ¤fªA¡B¨C¤é¤@¦¸ªº Janus ¿E酶1 (JAK1) §í»s¾¯¡A¥Î©óªvÀø±w¦³Ãøªv©Ê¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ (AD) ªº¦¨¤H¡A³o¨Ç±wªÌªº¯e¯fµLªk³q¹L¨ä¥L¥þ¨©ÊÃĪ«²£«~¡]¥]¬A¥Íª«»s¾¯¡^±o¨ì¥R¤À±±¨î¡A©ÎªÌ¦b¤£«Øij¨Ï¥Î³o¨ÇÀøªk®É¡C
CIBINQO ³Q§å㪺±ÀÂ˾¯¶q¬° 100 mg ©M 200 mg¡A200 mg ¾¯¶q³Q±ÀÂ˥Ωó¹ï 100 mg ¾¯¶q¨S¦³¤ÏÀ³ªº±wªÌ¡C¦¹¥~¡A50 mg ¾¯¶q³Q§åã¥Î©óªvÀø¤¤«×¦Ü««× AD¡A¯S§O¬O¦b¤¤«×µÇ¥\¯à¤£¥þ¡]µÇ°IºÜ¡^±wªÌ¡B¬Y¨Ç±µ¨ü²ÓM¦â¯À P450 (CYP) 2C19 §í»s¾¯ªvÀøªº±wªÌ¡A©Î¤wª¾©ÎºÃ¦ü¬O CYP2C19 ªº®z¥NÁª̡C¹ï©ó¤¤«×µÇ¥\¯à¤£¥þªº±wªÌ¡A¹ï¨C¤Ñ¤@¦¸ 50 ²@§J¨S¦³¤ÏÀ³ªº±wªÌ¡A¤]¥i¥H¶}¥X¨C¤Ñ¤@¦¸ 100 ²@§Jªº³B¤è¡C
¡§The reality for patients living with chronic inflammatory skin disease such as moderate-to-severe atopic dermatitis is that many experience debilitating symptoms that are not managed by current treatment options. Today¡¦s approval of CIBINQO will provide an important new oral option that could help those who have yet to find relief,¡¨ said Jonathan Silverberg, MD, PhD, MPH, Department of Dermatology, The George Washington University School of Medicine and Health Sciences. ¡§In multiple large-scale clinical trials, CIBINQO demonstrated strong efficacy at clearing skin, improving itch, and managing the extent and severity of eczema, offering a benefit-risk profile that supports the use of this treatment in the FDA-approved patient population.¡¨
FDA ªº§åã¬O°ò©ó 1,600 ¦h¦W±wªÌªº¤j³W¼ÒÁ{§É¸ÕÅçp¹ºªº¤¶µÁ{§É¸ÕÅ窺µ²ªG¡C CIBINQO ªº¦w¥þ©Ê©M¦³®Ä©Ê¦b¤T¶µÀH¾÷¡B¦w¼¢¾¯¹ï·Óªº 3 ´Á¸ÕÅ礤¶i¦æ¤Fµû¦ô¡C¦¹¥~¡A¦w¥þ©Ê³q¹L¤@¶µÀH¾÷¡B¦w¼¢¾¯¹ï·Ó¡B¾¯¶q½d³ò¸ÕÅç©M¤@¶µ¥¿¦b¶i¦æªºªø´Á¶}©ñ¼ÐÅÒÂX®i¸ÕÅç¶i¦æ¤Fµû¦ô¡C¦b¾ãÓ¸ÕÅ礤¡ACIBINQO ÃÒ©ú¤F»P¦w¼¢¾¯¬Û¤ñ¡A¹ï©ó¤@¨Ç±w¦³ AD ªº¤H¨Ó»¡¡ACIBINQO ¨ã¦³¤@Pªº¦w¥þ©Ê©M¥Ö½§²M°£²v¡B¯e¯fµ{«×©MÄY«µ{«×ªºÅãµÛ§ïµ½¡A¥H¤Î¨â¶g«áæ±Äoªº§Ö³t§ïµ½¡C¦¹¥~¡A»P¦w¼¢¾¯¬Û¤ñ¡A¦b¨â¶µ³æ¤@Àøªk¸ÕÅ礤±µ¨ü CIBINQO ªvÀøªº¨ü¸ÕªÌ¦b²Ä 12 ¶gªºæ±Äo§ïµ½ªº¤ñ¨Ò§ó°ª¡C
¡§¬ü°ê¹«~©MÃĪ«ºÞ²z§½ªº§å㬰¬ü°ê¼Æ¦Ê¸U¨C¤Ñ¾D¨ü§K¬Ìª¢¯g¯e¯f§é¿iªº±wªÌ±a¨Ó¤F§Æ±æ¡A¦pªG¤£¥[¥H±±¨î¡A¥i¯à·|¾ÉP¼@¯P©M«ùÄòªºæ±Äo¡B¯kµh¡B¤£¾A©MµhW¡A¡¨¥þ²yÁ`µô Mike Gladstone »¡¡C½÷·çª¢¯g»P§K¬Ì¾Ç¡C ¡§CIBINQO ¬O¤@ºØ¦³®Äªº¨C¤é¤@¦¸ÃĤY¡A¬O½÷·ç¬ã¨s¤Hû©M°Ñ»P§ÚÌÁ{§É¸ÕÅ窺¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢±wªÌ¹ê²{ªºÂå¾Ç¬ð¯}¡C¡¨
¡§¯SÀ³©Ê¥Öª¢¤£¶È¶È¬O¥Ö¯l¡A¥¦¶W¶V¤F¥Ö½§ªí±¡C³o¬O¤@ºØºC©Ê¯f¡A·|ÄY«ÂZ¶Ã±wªÌªº¤é±`¥Í¬¡¡A¨Ã¹ï¥L̪º±¡ºü°·±d²£¥Ít±¼vÅT¡A¡¨¥þ°êÀã¯l¨ó·|¥D®uݺ®u°õ¦æ©x Julie Block »¡¡C¡§§ÚÌ·PÁ½÷·ç¹ï³oÓ´I¦³¼u©Êªº±wªÌªÀ°Ïªº©Ó¿Õ¡A¨Ã¼ö¤Á´Á«Ý CIBINQO ¥i¯à¹ï¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ªºªvÀø«e´º²£¥Í¿n·¥¼vÅT¡C¡¨
≥5% ªº CIBINQO ±wªÌ³ø§iªº³Ì±`¨£¤£¨}¨Æ¥ó¥]¬A»ó«|ª¢¡]CIBINQO 100 mg ²Õ¬° 12.4%¡ACIBINQO 200 mg ²Õ¬° 8.7%¡A¦w¼¢¾¯²Õ¬° 7.9%¡^¡Bäú¤ß¡]6%¡B14.5% ©M 2.1% ¡A¤À§O¡^©MÀYµh¡]¤À§O¬° 6%¡B7.8% ©M 3.5%¡^¡C
CIBINQO ªº§¹¾ã³B¤è«H®§¥i¦b¦¹³B§ä¨ì¡CCIBINQO ±N¦b¥¼¨Ó´X¶g¤º´£¨Ñ¡C
CIBINQO Á{§É¸ÕÅçp¹ºªº¨ä¥L¸Ô²Ó«H®§
CIBINQO JAK1¯SÀ³©Ê¥Öª¢Àø®Ä©M¦w¥þ©Ê¡]JADE¡^¥þ²y¶}µop¹º¤¤ªº¤¶µÁ{§É¸ÕÅç³Q¯Ç¤J·sÃĥӽС]NDA¡^¥H¤ä«ùFDA§åã¡C
CIBINQO ªº¦w¥þ©Ê©M¦³®Ä©Ê¦b¤TÓ 3 ´Á¡BÀH¾÷¡B¦w¼¢¾¯¹ï·ÓÁ{§É¸ÕÅ礤¶i¦æ¤Fµû¦ô¡C³o¨Ç¸ÕÅçµû¦ô¤F¥Ö½§²M°£¡Bæ±Äo¡B¯e¯fµ{«×©MÄY«µ{«×ªº§ïµ½±¹¬I¡A¥]¬A½Õ¬dû¥þ²yµû¦ô (IGA)¡BÀã¯l±¿n©MÄY«µ{«×«ü¼Æ (EASI) ©M®pÈæ±Äo¼Æȵû©w¶qªí (PP-NRS)¡C¦b¨C¶µ¸ÕÅ礤¡A¶W¹L 40% ªº±wªÌ´¿±µ¨ü¹L¥þ¨ªvÀø¡G
JADE MONO-1 ©M JADE MONO-2¡G¤@¹ïÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¸ÕÅç¡A¦®¦bµû¦ô 778 ¦W±wªÌ 12 ¦~ªº¨âºØ¾¯¶q¡]100 ²@§J©M 200 ²@§J¨C¤Ñ¤@¦¸¡^ªº CIBINQO ³æ¤@ÀøªkªºÀø®Ä©M¦w¥þ©Ê¦~Ä֤ΥH¤Wªº¤¤«×¦Ü««× AD¡C³o¨Ç¸ÕÅç¦b²Ä 12 ¶gµû¦ô¤F IGA ©M EASI-75 ¤ÏÀ³ªº¦@¦P¥Dn²×ÂI¡C JADE COMPARE¡G¤@¶µÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¸ÕÅç¡A¦®¦bµû¦ô CIBINQO ¨â¾¯¡]100 ²@§J©M 200 ²@§J¡A¨C¤Ñ¤@¦¸¡^¦b 837 ¦WI´º§½³¡¥ÎÃĪº¤¤«×¦Ü««× AD ¦¨¤H±wªÌ¤¤ªºÀø®Ä©M¦w¥þ©ÊªvÀø¡C»P¦w¼¢¾¯¬Û¤ñ¡A¸Ó¸ÕÅçÁÙ¥]¬A¤@Ó±a¦³ dupilumab ªº¥D°Ê±±¨î²Õ¡Adupilumab ¬O¤@ºØ³q¹L¥Ö¤Uª`®g¶i¦æªº¥Íª«ªvÀø¡C¸Ó¸ÕÅç¦b²Ä 12 ¶gµû¦ô¤F IGA ©M EASI-75 ¤ÏÀ³ªº¦@¦P¥Dn²×ÂI¡C CIBINQO 100 mg¡B200 mg ©M¦w¼¢¾¯ªº¿ï¾Üµ²ªG¦p¤U¡]*p<0.01 ©Î **p<0.001¡^¡G
¥É³æÁn¹D-1¡G IGA ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 24%*¡B44%** ©M 8% EASI-75 ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 40%**¡B62%** ©M 12% JADE MONO-2 IGA ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 28%**¡B38%** ©M 9% EASI-75 ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 44%**¡B61%** ©M 10% ¥É¥Û¤ñ¸û IGA ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 36%**¡B47%** ©M 14% EASI-75 ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 58%**¡B68%** ©M 27% ¦w¥þ©ÊÁÙ³q¹L¤@¶µÀH¾÷¾¯¶q½d³ò¸ÕÅç©M¤@¶µªø´Á¡B¶}©ñ¼ÐÅÒ¡BÂX®i¸ÕÅç¡]JADE EXTEND¡^¶i¦æ¤Fµû¦ô¡C
¬ü°ê«n¦w¥þ«H®§
ĵ§i¡GÄY«·P¬V¡B¦º¤`²v¡B´c©Ê¸~½F¡B¥Dn¤£¨}¤ß¦åºÞ¨Æ¥ó©M¦å®ê§Î¦¨
ÄY«·P¬V
±µ¨ü CIBINQO ªvÀøªº±wªÌµo¥ÍÄY«·P¬Vªº·ÀI¥i¯à·|¼W¥[¡A±q¦Ó¾ÉP¦í°|©Î¦º¤`¡CCIBINQO ³Ì±`¨£ªºÄY«·P¬V¬O³æ¯Â¯p¯l¡B±aª¬¯p¯l©MªÍª¢¡C
¦pªGµo¥ÍÄY«©Î¾÷·|©Ê·P¬V¡A½Ð°±¤î CIBINQO ¨Ã±±¨î·P¬V¡C
¥Î©óªvÀøª¢¯gªº Janus ¿E酶 (JAK) §í»s¾¯³ø§iªº·P¬V¡G
¬¡°Ê©ÊªÍµ²®Ö¡A¥i¯àªí²{¬°ªÍ³¡©ÎªÍ¥~¯e¯f¡C¦bªvÀø«e©MªvÀø´Á¶¡ÀË´ú¼ç¥ñ©Êµ²®Ö¯f¡F¨Ï¥Î«eªvÀø¼ç¥ñ©Êµ²®Ö¯f¡C¦bªvÀø´Á¶¡ºÊ´ú©Ò¦³±wªÌªº¬¡°Ê©Êµ²®Ö¯f¡A§Y¨Ï¬O³Ìªì³±©Ê¡B¼ç¥ñ©Êµ²®Ö¯fÀË´úªº±wªÌ¡C «Iŧ©Ê¯uµß·P¬V¡A¥]¬AÁô²yµß¯f©MªÍÌU¤lÂίf¡C«Iŧ©Ê¯uµß·P¬V±wªÌ¥i¯à·|¥X²{¼½´²©Ê¦Ó«D§½³¡©Ê¯e¯f¡C ¥Ñ¾÷·|©Ê¯fìÅé¤Þ°_ªº²Óµß¡B¯f¬r¡]¥]¬A±aª¬¯p¯l¡^©M¨ä¥L·P¬V¡C ÁקK¦b¦³¬¡°Ê©Ê¡BÄY«·P¬V¡]¥]¬A§½³¡·P¬V¡^ªº±wªÌ¤¤¨Ï¥Î CIBINQO¡C¦b¶}©lªvÀøºC©Ê©Î½Æµo©Ê·P¬V±wªÌ©Î¦b¦a¤è©Êµ²®Ö¯f©Î¦a¤è©Ê¯uµß¯f¦a°Ï©~¦í©Î®È¦æªº±wªÌ¤§«e¡AÀ³¥J²Ó¦Ò¼{¨Ï¥Î CIBINQO ªvÀøªº·ÀI©M¯q³B¡C
À³±K¤ÁºÊ´ú±wªÌ¦b CIBINQO ªvÀø´Á¶¡©MªvÀø«á·P¬VÅé¼x©M¯gª¬ªºµo®i¡A¥]¬A¦b¶}©lªvÀø«e¹ï¼ç¥ñ©Êµ²®Ö·P¬VÀË´ú§e³±©Êªº±wªÌ¥i¯àµo®i¬°µ²®Ö¯f¡C
¦Ò¼{¨C¦~¹ïµ²®Ö¯f°ª«×¬y¦æ¦a°Ïªº±wªÌ¶i¦æ¿z¬d¡CCIBINQO ¤£±ÀÂ˥Ω󬡰ʩʵ²®Ö¯f±wªÌ¡C¹ï©ó·s¶EÂ_¬°¼ç¥ñ©Êµ²®Ö¯f©Î¥ý«e¥¼ªvÀøªº¼ç¥ñ©Êµ²®Ö¯f±wªÌ¡A©Î¼ç¥ñ©Êµ²®Ö¯fÀË´úµ²ªG¬°³±©Ê¦ý·P¬Vµ²®Ö¯f·ÀI°ªªº±wªÌ¡A¦b¶}©l CIBINQO ¤§«e¶}©l¹ï¼ç¥ñ©Êµ²®Ö¯f¶i¦æ¹w¨¾©ÊªvÀø¡C
¦b¨Ï¥Î CIBINQO ªºÁ{§É¬ã¨s¤¤³ø§i¤F¯f¬r¦A¿E¬¡¡A¥]¬A¯p¯l¯f¬r¦A¿E¬¡¡]¨Ò¦p¡A±aª¬¯p¯l¡B³æ¯Â¯p¯l¡^¡C¦pªG±wªÌ¥X²{±aª¬¯p¯l¡A¦Ò¼{¤¤Â_ CIBINQO ª½¨ìµo§@®ø°h¡C¦b±µ¨ü JAK §í»s¾¯ªº±wªÌ¤¤³ø§i¤F¤A«¬¨xª¢¯f¬r¦A¿E¬¡¡C¦b¶}©lªvÀø«e©M¨Ï¥Î CIBINQO ªvÀø´Á¶¡¡A®Ú¾ÚÁ{§É«ü«n¶i¦æ¯f¬r©Ê¨xª¢¿z¬d©M¦A¿E¬¡ºÊ´ú¡C¤£«Øij±N CIBINQO ¥Î©ó¬¡°Ê©Ê¤A«¬¨xª¢©Î¤þ«¬¨xª¢±wªÌ¡C
¦º¤`
¦b¤@¶µ°w¹ï 50 ·³¤Î¥H¤W¦Ü¤Ö¦³¤@ӤߦåºÞ¦MÀI¦]¯ÀªºÃþ·ÀãÃö¸`ª¢ (RA) ±wªÌ¶i¦æªº¤j«¬ÀH¾÷¤W¥««á¦w¥þ©Ê¬ã¨s¤¤¡A±N¥t¤@ºØ JAK §í»s¾¯»P TNF ªýº¢¾¯ªvÀø¶i¦æ¤ñ¸û¡Aµo²{§ó°ªªº¥þ¦]¦º¤`²v¡]¥]¬A¤ß¦åºÞÖ`¦º¡^ ) ¥Î JAK §í»s¾¯Æ[¹î¨ì¡CCIBINQO ¥¼³Q§åã¥Î©ó RA ±wªÌ¡C
´c©Ê¸~½F
¦b±µ¨ü CIBINQO ªvÀøªº±wªÌ¤¤³ø§i¤F´c©Ê¸~½F¡A¥]¬A«D¶Â¦â¯À½F¥Ö½§Àù (NMSC)¡C¦b±µ¨ü¥Î©óªvÀøª¢¯gªº JAK §í»s¾¯ªº±wªÌ¤¤Æ[¹î¨ì²O¤Ú½F©M¨ä¥L´c©Ê¸~½F¡C¹ï¥Ö½§Àù·ÀI¼W¥[ªº±wªÌ¶i¦æ©w´Á¥Ö½§Àˬd¡CÀ³³q¹L¬ï¨¾Å@ªA©M¨Ï¥Î¼sÃШ¾ÅÎÁ÷¨Ó¨î¼ÉÅS¦b¶§¥ú©Mµµ¥~½u¤U¡C
¦b¤@¶µ°w¹ï RA ±wªÌªº¥t¤@ºØ JAK §í»s¾¯ªº¤j«¬ÀH¾÷¤W¥««á¦w¥þ©Ê¬ã¨s¤¤¡A»P±µ¨ü TNF ªýº¢¾¯ªvÀøªº±wªÌ¬Û¤ñ¡A±µ¨ü JAK §í»s¾¯ªvÀøªº±wªÌªº´c©Ê¸~½F¡]¤£¥]¬A«D¶Â¦â¯À½F¥Ö½§Àù [NMSC]¡^ªºµo¥Í²v§ó°ª¡C CIBINQO ¥¼³Q§åã¥Î©ó RA ±wªÌ¡C»P±µ¨ü TNF ªýº¢¾¯ªvÀøªº±wªÌ¬Û¤ñ¡A±µ¨ü JAK §í»s¾¯ªvÀøªº±wªÌªº²O¤Ú½Fµo¯f²v§ó°ª¡C»P±µ¨ü TNF ªýº¢¾¯ªvÀøªº§l·ÏªÌ¬Û¤ñ¡A±µ¨ü JAK §í»s¾¯ªvÀøªº·í«e©Î¹L¥h§l·ÏªÌªºªÍÀùµo¯f²v§ó°ª¡C¥Ø«e©Î¹L¥h§l·Ïªº±wªÌ±Á{ÃB¥~¼W¥[ªº·ÀI¡C
¦b¶}©l©ÎÄ~Äò¨Ï¥Î CIBINQO ªvÀø¤§«e¦Ò¼{ÓÅé±wªÌªº¯q³B©M·ÀI¡A¯S§O¬O¹ï©ó¤wª¾´c©Ê¸~½F¡]¦¨¥\ªvÀøªº NMSC °£¥~¡^ªº±wªÌ¡B¦bªvÀø®Éµo¥Í´c©Ê¸~½Fªº±wªÌ¥H¤Î·í«e©Î¹L¥hªº±wªÌ§l·ÏªÌ¡C
¥Dn¤ß¦åºÞ¤£¨}¨Æ¥ó
¦b±µ¨ü CIBINQO ªvÀøªº±wªÌ¤¤³ø§i¤F¥Dn¤£¨}¤ß¦åºÞ¨Æ¥ó¡C¦b 50 ·³¤Î¥H¤W¥B¦Ü¤Ö¦³¤@ӤߦåºÞ¦MÀI¦]¯À¥B¨Ï¥Î¥t¤@ºØ JAK §í»s¾¯ªvÀøªº RA ±wªÌ¤¤¡AÆ[¹î¨ì¸û°ªªº¥Dn¤£¨}¤ß¦åºÞ¨Æ¥ó (MACE)¡]©w¸q¬°¤ß¦åºÞ¦º¤`¡B¤ß¦Ù±ð¶ë©M¤¤·¡^µo¥Í²v»P TNF ªýº¢¾¯¡C CIBINQO ¥¼³Q§åã¥Î©ó RA ±wªÌ¡C¥Ø«e©Î¹L¥h§l·Ïªº±wªÌ±Á{ÃB¥~¼W¥[ªº·ÀI¡C¦b¸g¾ú¹L¤ß¦Ù±ð¶ë©Î¤¤·ªº±wªÌ¤¤²×¤î CIBINQO¡C
¦b¶}©l©ÎÄ~Äò¨Ï¥Î CIBINQO ªvÀø¤§«e¦Ò¼{ÓÅé±wªÌªº¯q³B©M·ÀI¡A¯S§O¬O¦b·í«e©Î¹L¥h§l·ÏªÌ©M¨ã¦³¨ä¥L¤ß¦åºÞ¦MÀI¦]¯Àªº±wªÌ¤¤¡CÀ³§iª¾±wªÌÄY«¤ß¦åºÞ¨Æ¥óªº¯gª¬¥H¤Îµo¥Í®ÉÀ³±Ä¨úªº±¹¬I¡C
¦å®ê§Î¦¨
¦b±µ¨ü CIBINQO ªvÀøªº±wªÌ¤¤³ø§i¤F²`ÀR¯ß¦å®ê§Î¦¨ (DVT) ©MªÍ®ê¶ë (PE)¡C¦b±µ¨ü¥Î©óªvÀøª¢¯gªº JAK §í»s¾¯ªº±wªÌ¤¤³ø§i¤F¦å®ê§Î¦¨¡A¥]¬A PE¡BDVT ©M°Ê¯ß¦å®ê§Î¦¨¡C³\¦h³o¨Ç¤£¨}¤ÏÀ³¬OÄY«ªº¡A¦³¨Ç¾ÉP¦º¤`¡C»P TNF ªýº¢¾¯¬Û¤ñ¡A¦b 50 ·³¤Î¥H¤W¥B¦Ü¤Ö¦³¤@ӤߦåºÞ¦MÀI¦]¯À¥B¨Ï¥Î¥t¤@ºØ JAK §í»s¾¯ªvÀøªº RA ±wªÌ¤¤¡AÆ[¹î¨ì§ó°ªªºÁ`Åé¦å®ê§Î¦¨¡BDVT ©M PE µo¥Í²v¡CCIBINQO ¥¼³Q§åã¥Î©ó RA ±wªÌ¡C
¦b¦å®ê§Î¦¨·ÀI¥i¯à¼W¥[ªº±wªÌ¤¤ÁקK¨Ï¥Î CIBINQO¡C¦pªG¥X²{¦å®ê§Î¦¨¯gª¬¡A²×¤î CIBINQO ¨Ã¾A·íªvÀø±wªÌ¡C
¸T§Ò¯g
¦bªvÀøªº«e 3 Ó¤ë¡A°£§C¾¯¶qªü¥q¤ÇªL¡]¨C¤Ñ≤81 mg¡^¥~¡ACIBINQO ¸T¥Î©ó±µ¨ü§Ü¦å¤pªOªvÀøªº±wªÌ¡C
¹êÅç«Ç²§±`
¦å²G¾Ç²§±`¡GCIBINQO ªvÀø»P¦å¤pªO´î¤Ö¯g©M²O¤Ú²ÓM´î¤Ö¯gªºµo¥Í²v¼W¥[¦³Ãö¡C¦b CIBINQO ¶}©l¤§«e¡A°õ¦æ¥þ¦å²ÓMp¼Æ (CBC)¡C«Øij¦b¶}©l«á 4 ©P©M CIBINQO ¾¯¶q¼W¥[«á 4 ¶g¶i¦æ CBC µû¦ô¡C¬Y¨Ç¹êÅç«Ç²§±`»Ýn°±¤î CIBINQO ªvÀø¡C
¦å¯×¤É°ª¡G¦b±µ¨ü CIBINQO ªvÀøªº±wªÌ¤¤³ø§i¤F¦å¯×°Ñ¼Æªº¾¯¶q¨Ì¿à©Ê¼W¥[¡CCIBINQO ªvÀø¶}©l«á¬ù 4 ¶gÀ³µû¦ô¦å¯×°Ñ¼Æ¡A¦¹«áÀ³®Ú¾Ú°ª¯×¦å¯gÁ{§É«ü«n¹ï±wªÌ¶i¦æºÞ²z¡C³o¨Ç¯×½è°Ñ¼Æ¤É°ª¹ï¤ß¦åºÞµo¯f²v©M¦º¤`²vªº¼vÅT©|¥¼½T©w¡C
§K¬Ì±µºØ
¦b¶}©l CIBINQO ¤§«e¡A«ö·Ó·í«e§K¬Ì«ü«nªº«Øij§¹¦¨©Ò¦³¾A¦X¦~ÄÖªº¬Ì]±µºØ¡A¥]¬A¹w¨¾©Ê±aª¬¯p¯l¬Ì]±µºØ¡CÁקK¦b CIBINQO ªvÀø¤§«e¡B´Á¶¡©M¤§«á¥ß§Y±µºØ¬¡¬Ì]¡C
µÇ¥\¯à¤£¥þ
ÁקK¥Î©ó±w¦³ÄY«µÇ¥\¯à¤£¥þ©Î²×¥½´ÁµÇ¯fªº±wªÌ¡A¥]¬A±µ¨üµÇŦ´À¥NªvÀøªº±wªÌ¡C
¨x¥\¯à·l®`
ÁקK¦bÄY«¨x¥\¯à¤£¥þªº±wªÌ¤¤¨Ï¥Î¡C
¤£¨}¤ÏÀ³
±µ¨ü 100 mg ©M 200 mg ªº¨ü¸ÕªÌ³Ì±`¨£ªº¤£¨}¤ÏÀ³ (≥1%) ¥]¬A¡G»ó«|ª¢¡Bäú¤ß¡BÀYµh¡B³æ¯Â¯p¯l¡B¦å¦ÙÓþÁC»Ä¿E酶¤É°ª¡BÀY·w¡B§¿¸ô·P¬V¡B¯h³Ò¡BÚµ½H¡B¹Ã¦R¡B¤f«|µh¡B¬y·P¡B¸zGª¢¡C
±µ¨ü 100 mg ©Î 200 mg ªº¨ü¸ÕªÌ³Ì±`¨£ªº¤£¨}¤ÏÀ³ (≥1%) ÁÙ¥]¬A¡GÁw¯p¯f¡B°ª¦åÀ£¡B±µÄ²©Ê¥Öª¢¡B¤W¸¡µh¡B¸¡³¡¤£¾A¡B±aª¬¯p¯l©M¦å¤pªO´î¤Ö¯g¡C
Ãh¥¥´Á¶¡¨Ï¥Î
CIBINQO Á{§É¸ÕÅ礤³ø§iªº§³®Wªº²{¦³¼Æ¾Ú¤£¨¬¥H½T©w«¤j¥X¥Í¯Ê³´¡B¬y²£©Î¨ä¥L¤£¨}¥ÀÅé©ÎL¨àµ²§½ªºÃĪ«¬ÛÃö·ÀI¡C©¾§i¦³¥Í´Þ¼ç¤Oªº¤k©Ê CIBINQO ¥i¯à·|·l®`¥Í¨|¯à¤O¡C
±N¦³¤@Ó§³®W¼ÉÅSµn°O³B¡AºÊ´úÃh¥¥´Á¶¡¼ÉÅS©ó CIBINQO ªº°ü¤kªº§³®Wµ²ªG¡C¹ªÀy±µÄ² CIBINQO ªº¥¥°ü©MÂåÀø«O°·´£¨ÑªÌP¹q1-877-311-3770¡C
÷¨Å´Á
«Øij¤k©Ê¦b¥Î CIBINQO ªvÀø´Á¶¡©M³Ì«á¤@¦¸µ¹ÃÄ«á¤@¤Ñ¤£n¶i¦æ¥À¨Å³Þ¾i¡C
¾AÀ³¯g
CIBINQO ¾A¥Î©óªvÀø±w¦³Ãøªv©Ê¡B¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ªº¦¨¤H¡A¨ä¯e¯fµLªk³q¹L¨ä¥L¥þ¨©ÊÃĪ«²£«~¡]¥]¬A¥Íª«»s¾¯¡^±o¨ì¥R¤À±±¨î¡A©ÎªÌ¦b¤£«Øij¨Ï¥Î³o¨ÇÀøªk®É¡C
¨Ï¥Î¨î¡G¤£«Øij±N CIBINQO »P¨ä¥L JAK §í»s¾¯¡B¥Íª«§K¬Ì½Õ¸`¾¯©Î¨ä¥L§K¬Ì§í»s¾¯Áp¦X¨Ï¥Î¡C
Ãö©ó CIBINQO ® (abrocitinib)
CIBINQO ¬O¤@ºØ¿ï¾Ü©Ê§í¨î Janus ¿E酶 (JAK) 1 ªº¤fªA¤p¤À¤l¡C§í¨î JAK1 ³Q»{¬°¥i½Õ¸`°Ñ»P AD ¯f²z¥Í²z¾Çªº¦hºØ²ÓM¦]¤l¡A¥]¬A¥Õ²ÓM¤¶¯À IL-4¡BIL-13¡BIL-31¡BIL-22 ©M¯Ý¸¢°ò½è²O¤Ú²ÓM¥Í¦¨¯À (TSLP)¡C
°£¤F¦b¬ü°êÀò±oºÊºÞ§åã¥~¡ACIBINQO ÁÙ¦b¼Ú·ù¡B^°ê¡B¤é¥»¡BÁú°ê¡Bªü©Ô§BÁp¦X©ªø°ê¡B®¿«Â¡B¦B®q©M·s¥[©YÀò±o¤FÀç¾P³\¥i¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/19 ¤U¤È 10:00:25
²Ä 5071 ½g¦^À³
|
clinicaltrials.gov/ct2/show/NCT05158023?term=Aslan004&draw=2&rank=3
¦³µL¦¬®×¡A¬Ý¦¹ºô¯¸¡I
¥Ø«e©|¥¼¶}©l. ¤½¥q©|¥¼¤½¥¬¡A ¦b¤½¥qªºÂ²³ø¤¤¡A´£¥X¹wp¤¸¤ë¶}©l©Û¶Ò±wªÌ¡C
¬Ì±¡¼vÅT¡I¯à§_¤¸¤ë¶}©l¡H¤£ª¾¹D¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gonly10135877 |
µoªí®É¶¡:2022/1/19 ¤U¤È 09:16:14
²Ä 5070 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j ¨È·à±d ¤G´Á ¥Ø«e¦¬®×±¡ªp¦p¦ó,¤w¸g¦¬¨ì¯f¤H¤F¶Ü ÁÂÁ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/1/19 ¤U¤È 06:44:55
²Ä 5069 ½g¦^À³
|
·sÃĵ´¹ï¤ñ¹q¤l·~Ävª§ªº n¹À¦¨¥\n¹ÀÃz±¼¡A¨S¦³¨ººØ¥W¤[´N¬O§Aªº §Ú§ë¸ê·à¤l²{¦b«ÜÁŹF ·íµMÁÙ¬O§Æ±æ¥¦¦¨¥\Åý§ÚÁÈ¿ú ¦ý¦pªG¬O§Ú¬Ý¨«²´§Ú¤]»{¤F ¤]¦¦³¥þ³¡Ãz±¼ªº¤ß²z·Ç³Æ §ë¸ê¤Á°Oµ´¤£n³æÀ£¡A¦n¼Ðªº¥Ã»·¤£¥u¤@Ó |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2022/1/19 ¤U¤È 06:23:00
²Ä 5068 ½g¦^À³
|
·PÁ¤ѩR¤jªº¤À¨É¬Ýªk¡C ¥H«eı±o¹q¤l·~Ävª§¤Ó¿E¯P¡A¤Ó®£©Æ¡A ²{¦b¬Ý°_¨Ó¡AÃĤ]¶W¯ÅÄvª§¡A ¦PÓ¾AÀ³¯g¡A³o¼Ë¦h¤H¦b°l³v¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/19 ¤U¤È 05:01:57
²Ä 5067 ½g¦^À³
|
AD¥¼¨Ó240»õ¬ü¤¸¥«Ô·¡K¡K2029¦~/¥Íª«»s¾¯¡C
¨Ì¤W½g¤å³¹¡A±M·~¤½¥qµû¦ô¡A10»õ¬ü¤¸¤fªAADÃľP°â
½÷·ç¦Ûµû30»õ¬ü¤¸¡A³Ì°ª销°â¡C
°Æ§@¥Î¡K¡Kªø´Á¨Ï¥Î¤~¬O¬D¾Ô¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2022/1/19 ¤U¤È 04:39:24
²Ä 5066 ½g¦^À³
|
news.gbimonthly.com/tw/article/show.php?num=45843&range=news ½Ð敎¤@¤U ¤Ñ©R¤jªº¬Ýªk¡A³oÓÃĹï©óASN004ªº¼vÅT¦p¦ó¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/19 ¤W¤È 11:03:17
²Ä 5065 ½g¦^À³
|
³¯¤j¡A
§Ú¦Û¤v¤]n¤p¤ßµo¨¥¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/1/19 ¤W¤È 10:56:07
²Ä 5064 ½g¦^À³
|
¤Ñ©R¤j §Ú»{¦P§A¹ï¨È·à±d¥I¥X¤Î»{¯u·j¶°¸ê®Æ §ë¸êªÌ¹ï¤½¥q§@¬°´£¥X½èºÃ,¥Îµü¨Ï¥Î¥i¯à¡BÃhºÃ¡AÀ³µL¤£·í
ªÑ»ù¶^¦Ü¦¹¥Ð¦a¡AÃø¨ìºÞ²z¶¥¼h¤£¥ÎÀË°Q¤Ï¬Ù§ïÅܶܡAÁÙn¹ï¨äºq¥\¹|¼w¶Ü
¨¥µü¦p¦³ªk«ß³d¥ô¡A½Ð¤½¥q´£§i¡A§ÚµL©Ò¬ÈÄß
³ÓªÌ¬°¤ý¡A±ÑªÌ¬°±F¡A
CEO Carl FirthÀ³t¥þ³d¡A¹ïªÑªF¥æ«Ý
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2022/1/19 ¤W¤È 10:21:36
²Ä 5063 ½g¦^À³
|
CSL³o¤j¼t·íµM¤£·|°²~¦ý004¯à¤£¯à¦¨¥\¤£¬O§A»¡¤Fºâ~¸g¹L¦UºØÁ{§É¸ÕÅç¼Æ¾Ú¤ÀªR«á¤~¬O³Ì«áªºµ²ªG~³o¹Lµ{¦Ü¤Ön´X¦~¥H¤W,²{¦b§AÂ_¨¥®³¨ìÃÄÃÒ¤£¬O°ÝÃD ! ¬O¤£¬O¤]¬Oºô¸ô³yÁÁ ? µM«á¶¡±µ®`ºG¤F¤@¨Çª¼¥Øªº§ë¸ê¤H ?
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/1/19 ¤W¤È 08:51:00²Ä 5060 ½g¦^À³ ³¯¤j¡A
¤½¥q¤½§i¸êÖö³y°²¡A¸g²z¤H须¥I¦D¨Æ责¥ô¡C
¬ü°ê§ë¸ê¤j衆¡AªÑªF¥Á¨Æ¨DÀvª÷额«D±`°ª¡C
ASLAN004 ªºMOA¡A¦¤w³Qdupilumab, Tarol,Lerb
¤TÃÄ©Òµý¡A¥i¦P®Éªý断IL4/IL13 °²¤£¤F¡C
®³Ãĵý¤£¬O°ÝÃD¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/19 ¤W¤È 10:01:03
²Ä 5062 ½g¦^À³
|
Aslan004 , ±ÂÅv¨Ó¦ÛCSL(¿D¬w¤jÃļt¡A¥«È¤@¥ü¥x¹ô¡A2¸U员¤u)
ñ¬ùª÷7.8»õ¬ü¤¸¡C+¤À¼í
³o¤£·|°²¡C
2019/05...
ASLN ¦@¦P¶}µo¡A¨É¦P¼Ë»ùÈ¡C
现ªp»ùÈ¡A¦Ü¤Ö½¿¡C ¦A¥[2bÁ{§É»ùÈ¡C
¨C¤@Ó¤À¤l«J¿ï·sÃÄ¡AÄvª§Àô¹Ò¬Ò¤£¦P¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2022/1/19 ¤W¤È 09:59:39
²Ä 5061 ½g¦^À³
|
¶ZÂ÷¤W¦¸¯d¨¥(2021/12/28)¹L¤F¤j¬ù20¤Ñ~¨ì¤F¤µ¤Ñ¥Ø«e¤w¸g¶^¸¨1¶ô¤§¤U... (2021/9/29)¸Ñª¼¤j¶^¤§®ÉÁÙ¦³2.5¶ô,¥B·í®É¥»¤H¤w¸gÂ_¨¥¤§«áÁÙ·|«ùÄò¤j¶^... ¬Ýªk¨Ì¤£ÅܱNÄ~Äò©¹0.8¾aªñ~¦A¨Ó´N¬O©¹0.5»ù¦ì¾aÃl.... ¤d¸U¤£n¬Û«H±Ë»ò³o·sÃĤñ±Ë»òÁÙn¦nªº°¸Ü ? §Aª¾¹D¥«±¤W¾AÀ³©Ê¥Ö½§ª¢·sÃĦ³¦h¤Ö¶Ü ? ª¾¹D¤F§A´N¤£·|Ä~Äò§ë¸êASLN¤F....
³¯¤j§Aªºµo¨¥¨S¦³°ÝÃD~¤£»Ýn³Q¤H«Â¯Ù~~¤]¤£·|¦³ªk«ß³d¥ô !
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/12/28 ¤U¤È 01:43:58²Ä 5008 ½g¦^À³ ¥H¤U¬O2021/9/29¸Ñª¼¨ì¤µ¤Ñªº¬Ýªk.... ¥»¤H1´Á¸Ñª¼¤j¶^·í¤Ñ¬å¥X»ù¦ì2¶ô5¥ª¥k!!¨ì¤µ¤Ñ¤S¶^¨ì1¶ô¿ú¤W¤U~²{¦bªºªÑ»ù¤w¸gÅçÃÒ·í®Éªº¬Ýªk~ ¤§«áÁÙ·|©¹0.8¾aªñ~¤£«H¶Ü ? ½Ð±µµÛ¬Ý !! ºô¸ô°g´öªGµMÁÙ¬O·|¨R©ü¤@°ï¤H°Ú~½Ð¦Û¤v¤p¤ß!!
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/23 ¤U¤È 05:55:34²Ä 4784 ½g¦^À³ ¬Q¤é«ùÄò¤j¶^7%¤¤~«Ü¼y©¯¥»¤H¦b¨È·à±d¬ü¤Æªº1´Á¸Ñª¼¼Æ¾Ú..¦ý¥«³õ¤£»{¦P¤j¶^«á...¦b2¶ô¦h´N¥þ¼Æ¥X²æ.. ¤§«e¤w¸g»¡¹LªGµM¤j¶^«áÁÙ·|«ùÄò³Ð·s§C...¥¼¨Ó±NºCºC½w¶^¨ì¤@¶ô¤§¤U..¤d¸U¤£n¤£¬Û«H ?
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/15 ¤U¤È 07:49:46²Ä 4750 ½g¦^À³ ¥H¤U§ó¥¿¬°004 ¤j®aÁÙ°O±o¶Ü¡H ¨È·à±d³£¬O¤@³eªº§@·¡A¤§«eÁx¹DÀù¤T´Á¥¼¸Ñª¼¤§«e¤]¬O³£«Ü¼ÖÆ[¡AµM«á³oÃ䪺ºô¤Í±M·~¤ÀªR¤å³¹³sµo¡I»¡¦³¦h¼F®`¤@©w·|¹L¤T´Á¡Aµ²ªG¤@¸Ñª¼¥¢±ÑªÑ»ù¤j¶^¡A³oÃ䪺ªº°l±·¤å³¹ÃÒ¾Ú¤]³£¤@°_¬å±¼¤F¡AµM«á²{¦b¦A¨ÓÓ004¡K ¬Ý¦ü«Ü±M·~¼Æ¾Ú¤å³¹Ä~Äò°l±·¡A¦ý¨Æ¹ê004´N¬O¼Æ¾Ú¤£¦n¡AÃø¤£¦¨¨gµo¬Ý¦ü±M·~ªº¤å³¹¡A¨È·à±d´N·|ùL¤G´Á¶Ü¡HµM«á³Q¦¬ÁÊ¡H ·í§½ªÌ°g¡A®ÇÆ[ªÌ²M¡A½Ð¤T«ä¡K
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/12 ¤U¤È 03:24:19²Ä 4709 ½g¦^À³ Ó¤Hı±o³o¦¸¤£¬OÀ£§C¥X³f¸ÑŪ, ¦U¦ì¦³¬Ý¹L¼Æ¾ÚÀu¦ý¬OªÑ»ù¶^±¼¤@¥bªºªº¨Ò¤l¶Ü? ³q±`¼Æ¾ÚÀu³£¬Oº¦¤@¿!¤£·|À£§CÅý§A¦Y³fªº©Ô! ¨S·N¥~ªÑ»ù·|½w¶^¨ì1¶ô¤§¤U~
¥H¤U¬O9¤ë©³ªº¬Ýªk¦Ü¤µ¤£ÅÜ...½w¶^¨ì§A¤ß·W·N¶Ã...
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤W¤È 08:53:03²Ä 4663 ½g¦^À³ ¥H¤U¬O 9/29 ªº¬Ýªk ¦Ü¤µ¤£ÅÜ
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/9/29 ¤W¤È 09:06:30²Ä 4559 ½g¦^À³ ¬Û«H¶R¨È·à±dªº¦U¦ì¤j¤j,¥¼¶}¼ú¤§«e³£¦bÀqÀq½Lºâ,§Úªº¦Ê¸U§ë¸ê¦b¤E¤ë¸Ñª¼«á·|½¦¨¦n´X¿·Ç³Æ¶R¨®¶R©Ð¤F,¦ý³o¦¸¶}¼úµ²ªG´N¬O¤£¦p¹w´Á,§Ú¥i¥H§i¶D¦U¦ì°ê¥~¦U§ë¸ê¶R®a¹Î¶¤¬O¤£¶R³æªº,¤]¤£n¬Û«H±Ë»ò§ë¸ê¾÷ºcµ¹¥Ø¼Ð»ù8¶ô¿ú(³o¨Ç³£¬O½æªÅªº¦nªB¤Í,§Aªº¿ú³£¬O³Q³o¨Ç½æªÅªÌÁȨ«)! °ê¥~ªº§ë¸ê¹Î¶¤¤£¬Oªxªx¤§½ú,I«á¬ã¨s¹Î¶¤ªº¥\¤O¤£ª¾¹D±j¹L³oÓª©ªº¬Y¨Ç¤ÀªR¼Æ¦Ê¿!¤]¤£·|¸ò§AºtÀ¸..¦n¼Æ¾Ú´N¬O¤j¶R,Äê¼Æ¾Ú´N¬O¤j½æ! ¦pªG¯uªº¹Ú¿ô¤F´NÅý¥L¿ô§a,¤d¸U¤£n¨I¾K¦b¹Ú¸Ìn¶}©l¾Ç·|±¹ï²{¹ê ! ¬üªÑºD©Ê¦pªG¤j¶^«áªº¹j¤ÑÁÙ¬O¤j¶^,¤§«áªº¼Æ©P±N·|«ù³Ð·s§C,¤£«H¶Ü ?11¤ë1¤é¤j®a¨ÓÅçÃÒ !
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤U¤È 02:49:51²Ä 4668 ½g¦^À³ ¥«³õ¤W°µÃþ¦üªºÃįuªº¤Ó¦h¤F~³Ìªñ1¦~¨Ó¦³´X®a¬Û¦PÃĪ«1´Á¸Ñª¼«á³£¤jº¦5¦¨~1¿¥H¤W,¦ý¥u¦³¨È·à±d¦V¤U¶^±¼¤@¥bªÑ»ù¥H¤W, ¦pªG¯uªº¦p³oÓªO¤W¤ÀªRªº¼Æ¾Ú¨º»ò¦n,ªÑ»ù¬°¦óÁÙ¬O«®À??Ãø¹D¬O¨º¨Ç§ë¸ê¾÷ºc¥þ³¡¬Ý¨«²´½M¤F¤£±¤¦¨¥»¤@¸ô¨g½æ? ¨Æ¹ê¬O¨È·à±dªº¼Æ¾Ú´N¬O®t©ó¹w´Á,¤§«á¤]¤£·|¦³±Ë»ò¤H·|¨Ó½Í±ÂÅv©Î¬O¨ÖÁÊ,ªÑ»ù±N·|½L¶^¨ì1¶ô¿ú¥H¤U....
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤W¤È 08:53:03²Ä 4663 ½g¦^À³ ¥H¤U¬O 9/29 ªº¬Ýªk ¦Ü¤µ¤£ÅÜ
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/9/29 ¤W¤È 09:06:30²Ä 4559 ½g¦^À³ ¬Û«H¶R¨È·à±dªº¦U¦ì¤j¤j,¥¼¶}¼ú¤§«e³£¦bÀqÀq½Lºâ,§Úªº¦Ê¸U§ë¸ê¦b¤E¤ë¸Ñª¼«á·|½¦¨¦n´X¿·Ç³Æ¶R¨®¶R©Ð¤F,¦ý³o¦¸¶}¼úµ²ªG´N¬O¤£¦p¹w´Á,§Ú¥i¥H§i¶D¦U¦ì°ê¥~¦U§ë¸ê¶R®a¹Î¶¤¬O¤£¶R³æªº,¤]¤£n¬Û«H±Ë»ò§ë¸ê¾÷ºcµ¹¥Ø¼Ð»ù8¶ô¿ú(³o¨Ç³£¬O½æªÅªº¦nªB¤Í,§Aªº¿ú³£¬O³Q³o¨Ç½æªÅªÌÁȨ«)! °ê¥~ªº§ë¸ê¹Î¶¤¤£¬Oªxªx¤§½ú,I«á¬ã¨s¹Î¶¤ªº¥\¤O¤£ª¾¹D±j¹L³oÓª©ªº¬Y¨Ç¤ÀªR¼Æ¦Ê¿!¤]¤£·|¸ò§AºtÀ¸..¦n¼Æ¾Ú´N¬O¤j¶R,Äê¼Æ¾Ú´N¬O¤j½æ! ¦pªG¯uªº¹Ú¿ô¤F´NÅý¥L¿ô§a,¤d¸U¤£n¨I¾K¦b¹Ú¸Ìn¶}©l¾Ç·|±¹ï²{¹ê ! ¬üªÑºD©Ê¦pªG¤j¶^«áªº¹j¤ÑÁÙ¬O¤j¶^,¤§«áªº¼Æ©P±N·|«ù³Ð·s§C,¤£«H¶Ü ?11¤ë1¤é¤j®a¨ÓÅçÃÒ ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/19 ¤W¤È 08:51:00
²Ä 5060 ½g¦^À³
|
³¯¤j¡A
¤½¥q¤½§i¸êÖö³y°²¡A¸g²z¤H须¥I¦D¨Æ责¥ô¡C
¬ü°ê§ë¸ê¤j衆¡AªÑªF¥Á¨Æ¨DÀvª÷额«D±`°ª¡C
ASLAN004 ªºMOA¡A¦¤w³Qdupilumab, Tarol,Lerb
¤TÃÄ©Òµý¡A¥i¦P®Éªý断IL4/IL13 °²¤£¤F¡C
®³Ãĵý¤£¬O°ÝÃD¡I
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K
³¯¤j ½Ð¤p¤ß±zªºµo¨¥¡Aºô¸ôµo¨¥¡A须负ªk«ß³d¥ô¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/1/19 ¤W¤È 08:23:06
²Ä 5059 ½g¦^À³
|
¤Ñ©R¤j¤j CNTB «®À«áªÑ»ù¤w¤î¶^
¨È·à±d°Ñ¥[®L«Â¦i¥Í§Þ·|ij »¡©ú1b¼Æ¾Ú¤º®e«á¡A¥«³õ¤´¤£¶R³æ ¤w«ùÄò¤U¶^§Ö4Ó¤ë
§Ú»{¬°³o®a¤½¥q«e¬ì¤£¨}¡A¸Û«H¦³°ÝÃD
»¡¤°»ò³£¨S¥Î¤F ¬Æ¦ÜÃhºÃ¸Ó¤½¥q¼Æ¾Ú¦³³y°²¥i¯à ·|¤£·|¯uªº¤W¤F¸é²î
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/19 ¤W¤È 08:01:30
²Ä 5058 ½g¦^À³
|
finance.yahoo.com/news/connect-biopharma-reports-detailed-positive-120000978.html
Cntb 201 Ad 2b ¸Ô²Ó³ø§i¡A
¤ñ§ÚÌ®t¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/1/19 ¤W¤È 07:15:23
²Ä 5057 ½g¦^À³
|
³s¶^4Ó¤ë ³Ñ0.99¤¸¡AÁÙ¦³¾÷·| |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/15 ¤W¤È 07:22:07
²Ä 5056 ½g¦^À³
|
2b ³W¹º©Û¶Ò295¤H¡A5组Á{§É¡A
295/5=59¡A±N¤À59Ó©Û¶Ò¤¤¤ß©Û¶Ò¡C
¦ôp©Û¶Òªº¥§¡EASI³W¹º27-30(ªñLebrekiumab)¡A
À³·|¤j´T°§C«D¨å«¬ADªº¤ñ²v (¥Ñdupilumab 3´Á¡A§CTRAC组±À¦ô10%-15%¡A004 1b¨ä¥L¤¤¤ß«D¨åAD¦ô13%)¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/15 ¤W¤È 06:54:48
²Ä 5055 ½g¦^À³
|
1b ªºITT 38¤H¡A
¶°¤¤¤@Ó¤¤¤ß9¤H¡A³o¤£¬OÀH¾÷¨ú¼Ë¡A¹J¬Ì±¡¡H
©Ò¥H»¡¡A¥»¨Ó©Û¶Ò»´¯gªº³W¹º¬O°e¤À题 À³¹FEASI¥§¡°90%¡A ¦ý«D¨å«¬(¥i¯à«DIL4/IL13¾÷Âà)¯f±w¡A³Ì«á¡«áEASI¥§¡°50%¡C
(Dupilumab ¤T´Á¡A§CTRAC¡A¡«á¥§¡°78%)
µ²½×:¤½¥q¥h±¼9¤H(¤@¤¤¤ß¡A«D¨åAD)±Ó·P«×¤ÀªR¡A«Ü¦³°Ñ¦Ò©Ê©Ê¡C¯uªº¤ñDupilumab¤T´ÁÀu¾÷·|°ª¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/1/14 ¤U¤È 11:45:23
²Ä 5054 ½g¦^À³
|
¬Ý§¹ P21 p22 ©ñ¤ß«Ü¦h
³o¬O¤½¥q¦A«×ÀË°Q¦³¤@Ó©Û¶Ò¯¸¦@9¦W¨ü¸Õ ( ¥l¨ì¤£¨å«¬¯f±w) ( ¨ú¼Ë°¾®t¼vÅT¼Æ¾Ú) 1 TARC: ¤ñ¨ä¥L©Û¶Ò¯¸TARC§C ( TARC 0.5-1.1 ng/ml)(¨ä¥L¯¸ TARC4.7ng/ml)(Dupilumab TARC 4.8-6.2 ng/ml ) 2IgE: ¤ñ¨ä¥L©Û¶Ò¯¸¹L§C ¤]¤ñDupilumab§C 3 ¶Ý»Ä©Ê¥Õ¦å²y¼Æ¤ñ¨ä¥L©Û¶Ò¯¸§C 4 89%¨S¦³¹L±Ó¦X¨Ö¯g (¤ñ¨ä¥L©Û¶Ò¯¸¥u¦³13%¨S¦³¹L±Ó¦X¨Ö¯g (°ª«Ü¦h)
¬°¤Fºë·Ç¥l¶Ò¯f±w¥²»Ý§äIQVIA Biotech¦X§@¥H´£°ªÁ{§É¸ÕÅ禨¥\¾÷²v
IQVIA Biotech¡A¤@®a¬°¥Í©R¬ì¾Ç¦æ·~´£¨Ñ¥ý¶i¤ÀªR¡B§Þ³N¸Ñ¨M¤è®×©MÁ{§É¬ã¨sªA°Èªº¥þ²y»â¥ý¨ÑÀ³°Ó¡A§@¬°¨ä»P¤À´²Á{§É¸ÕÅç¬ÛÃöªºª«¬yªºº¿ïÁ{§É¬ã¨s²Õ´¡A¥]¬A¥þ²yºÊ·þ¡BÂX®i©M±wªÌ°Ñ»P¥Î©ó»P ASLAN004 ©M ASLAN003 ªºÁ{§É¶}µo¬ÛÃöªº¸ÕÅç¡CIQVIA Biotech ±N¬° ASLAN §Y±N¦b±w¦³¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ªº¦¨¤H¤¤¶i¦æªº 300 ¦W±wªÌ ASLAN004 2b ´Á¸ÕÅç´£¨Ñ±wªÌ©Û¶Ò¡BÁ{§ÉºÊ´ú¡BÂå¾Ç¼g§@©M¥Íª«²Îp¾Ç¡C IQVIA Biotech ±N»P ASLAN ªººÞ²z¼h±K¤Á¦X§@¡AºÊ·þ¬ü°ê¡B¥[®³¤j¡B¼Ú¬w©M¨È¬wªºÁ{§É¹BÀç©M±wªÌ©Û¶Ò¡C IQVIA Biotech ÁٷdzƻP ASLAN ªºÁ{§É¹BÀç¹Î¶¤´N ASLAN003¦bª¢¯g©Ê¸z¯fIBD ªº¥¼¨Óµo®ip¹º¶i¦æ¦X§@¡AÁ{§É¸ÕÅç±N©ó©ú¦~ªì¶}©l
¸É¥R: ¶Ý»Ä©Ê¥Õ¦å²y¼Æ: ²§¦ì©Ê¥Ö½§ª¢ªº±wªÌ¡A¶Ý»Ä©Ê¥Õ¦å²yªº¼Æ¶q¸û¦h¡C IgEÈ¡]§K¬Ì²y³J¥Õ¡^ : IgE¬O«OÅ@¨Å餣¨ü¹L±Óì«IÂZªº¤@ºØ§ÜÅé¡CY¼ÆÈ°ª¡A«hªí¥Ü¥i¯à¹ï¬Y¨ÇªF¦è¹L±Ó¡C TARCÀˬd¡]Thymus and activation-regulated chemokine¡^µû¦ô²§¦ì©Ê¥Ö½§ª¢¯gª¬µ¥¯Åªº¼ÆÈ¡C¯gª¬¶VÄY«¡A¼ÆȶV°ª¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/1/14 ¤U¤È 08:37:22
²Ä 5053 ½g¦^À³
|
§Y±N¶}©lªº2Ó·|ij¤£¦P¥H©¹ ªº¬O³o¦¸ªº¥D¨¤¬O karen veverka³Õ¤h¡A¤£¬O³Å«i À³¸Ó·|¦³¨Ç§ó±M·~ §ó²`¤Jªº¤@¨Ç³ø§i §Æ±æ¯à±a¨Ó¨Ç¦n®ø®§ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/1/14 ¤U¤È 01:46:46
²Ä 5052 ½g¦^À³
|
§Ú²qÀ³¸Ó´N¥u¬O³ø§i²³ø¤Wªº¸ê®Æ¦Ó¤w |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/1/14 ¤U¤È 01:33:23
²Ä 5051 ½g¦^À³
|
111.01³Ì·s²³ø
ir.aslanpharma.com/static-files/2a7f1481-a0b3-47d1-87ef-e6ed30321475
§Æ±æ¦b®L«Â¦iªº¨â³õ·|ij¯à¦³·sªF¦è¦V¥«³õ®i¥Ü~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/1/12 ¤U¤È 01:34:09
²Ä 5050 ½g¦^À³
|
Y¯à¦³©µ¦ù¦Ü12©Î16¶g(³Ì¦n¬O16¶g)ªº¥¿¦V¼Æ¾Ú¡A¨º¦³¾÷·|Åý¥«³õ»{¦P~~~~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/1/11 ¤U¤È 09:25:19
²Ä 5049 ½g¦^À³
|
¤½¥q±N¦b1¤ë¤¤¤U¦¯§e²{·§©À©ÊÅ祿¤¤´£¨ÑÃB¥~¸ê®Æ (¨âÓ·|ij¤¤¤½§i§¹¾ã¾¯¶q»¼¼W¸ê®Æ) (2021¦~3¤ë1¤é¤½§iªº¥u¬O´Á¤¤¤ÀªR14¤H--18¤H¸ê°T )
ASLAN PHARMACEUTICALS TO PRESENT ADDITIONAL DATA FROM ASLAN004 PROOF-OF-CONCEPT STUDY AT TWO UPCOMING WINTER DERMATOLOGY CONFERENCES
- Data from Phase 1b dose escalation cohorts to be presented during the 2022 Winter Clinical Dermatology Conference, held in-person from 14-19 January, 2022, in Koloa, Hawaii
- Data will also be presented as an encore presentation at the MauiDerm Conference, held inperson and virtually from 24-28 January, 2022, in Maui, Hawaii
Menlo Park, California, and Singapore, 11 January, 2022 ¡V ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that the results from the dose escalation portion of the completed Phase 1b Proof-ofConcept study of ASLAN004 in atopic dermatitis (AD) have been accepted for poster presentation at the 2022 Winter Clinical Dermatology Conference, to be held in Koloa, Hawaii, January 14-19, 2022. The poster will provide further details on the safety, tolerability and efficacy of ASLAN004 in the dose escalation portion of the multiple ascending dose study in 25 patients. The Company also announced these data will be presented in an encore presentation at the MauiDerm Conference, held in Maui, Hawaii, January 24-28.
ASLAN004 is a potential first-in-class monoclonal antibody targeting the IL-13 receptor, with the potential to deliver a differentiated safety and efficacy profile as well as an improved dosing regimen for patients. In September 2021, ASLAN announced positive results from the Phase 1b Proof-of-Concept study and supported its potential as a differentiated, novel treatment for AD. 2022 Winter Clinical Dermatology Conference Poster details Title: Interim analysis results from a Proof-of-Concept study for ASLAN004 in adult moderate-to-severe atopic dermatitis: a double blind, randomized, placebo-controlled study
Presenter: Dr Karen Veverka, VP Medical, ASLAN Pharmaceuticals
Location: Poster Gallery, Grand Promenade of the Grand Hyatt Kauai
Viewing dates: 15-18 January 2022
The poster will be available to view online in the Investor Relations section of ASLAN¡¦s website following
presentation: ir.aslanpharma.com/. The poster results will also be presented in-person as an encore presentation at the MauiDerm Conference from 24-28 January 2022.
More information on the presentations available during the events can be found here: fallclinical.health/wc22-agenda mauiderm.com/maui-derm-dermatologists-2020-program-2-2-2-3/
2021¦~3¤ë1¤é¤½§iªº¬O´Á¤¤¤ÀªR14--18¤H¸ê°T The first three cohorts randomised 25 patients from the United States, Australia and Singapore. Three patients discontinued study due to restrictions imposed in response to COVID-19. Of the remaining 22 patients, 18 completed at least 29 days of dosing and assessment and were evaluable for efficacy. • The average baseline Eczema Area Severity Index (EASI) score of patients was 32.5 and the average Investigators Global Assessment (IGA) score was 3.4 (n=18). • At week 8, the average reduction in EASI from baseline at therapeutic doses (400mg and 600mg cohorts) was 74% (n=9) compared to 42% (n=5) for patients on placebo. o 89% achieved EASI-50 versus 40% on placebo; o 67% achieved EASI-75 versus 0% on placebo; o 56% achieved EASI-90 versus 0% on placebo. • 22% of patients achieved IGA of 0 or 1 at therapeutic doses versus 0% on placebo. • Peak pruritus improved after just one dose and continued to improve by an average of 46% relative to baseline at 8 weeks compared to 16% for patients on placebo. • The proportion of patients with adverse events and treatment-related adverse events were similar across treatment and placebo arms. There were no treatment-related adverse events in the active arm that led to discontinuation. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/11 ¤W¤È 07:04:31
²Ä 5048 ½g¦^À³
|
¦ò»¡¬G¨Æ:(µØªk¤CûG) (¤@¡^¡qÄ´³ë«~¡rªº¡u¤õ¦v³ë¡v
¤õ¦v³ë¡A¤SºÙ¡u¤T¨®¤õ¦v³ë¡v¡C¤T¨®¬O«ü¡G¦Ï¨®¡]¤p¨®¡^¡B³À¨®¡]¤¤¨®¡^¡B¤û¨®¡]¤j¨®¡^¡C¦òªû¥H¥©§®«Å»¡¡u¤T¬É¤õ¦v³ë¡v¡A©óÄ´³ë¤¤¼s»¡¡u©ó¤@¦ò¼¡A¤À§O»¡¤T¡v¤§¡u¶}¤TÅã¤@¡vªº¹D²z¡C
¦³¤@ÓªøªÌªº¤p¨à¡B¤p¤kÌ¥¿¦b©Ð¤¤¼^À¸¡A©Ð¤l¬ðµM°_¤õ¤F¡AªøªÌ¥s¹D¡G¡u§ÖÂI°k¥X¥h§r¡I©Ð¤l°_¤õ¤F¡I¡v«Ä¤lÌ¥¿ª±±o¦³¿³P¡A¤£¬Û«H©Ð¤lµÛ¤õ¤F¡A¤÷¿Ë¨S¦³¿ìªk¡A¥u¦n»¡¡G¡uªù¥~¦³¦Ï¨®¡B³À¨®¡B¤û¨®¡A§¤¤W¥h¥H«á¡A¥i¥H¥|³B©b¶]¡A«Ü¦nª±ªº¡I¡v«Ä¤l̬°¤F±o¨ì¦Ï¨®¡B³À¨®©M¤û¨®¡A³£ª§¥ý®£«áªº¶]¥X¤F©Ð¤l¡CªøªÌº¡¤ßÅw³ß¡A½çµ¹¥L̨C¤H¤@½ø¤j¥Õ¤û¨®¡C
Ä´³ë¤¤ªº¦Ï¨®¥NªíÁn»D¼¡A¦Ïªº¤O®ð¤p¡A¥u¯à©Ô¤@Ó¤H¡F³À¨®¡A¤ñ³ë½tı¼¡A¤]¬O¤p¼¡F¤ûªº¤O®ð¤ñ¸û¤j¡A¯à¦h©Ô´XÓ¤H¡A©Ò¥H¬O¤j¼µÐÂÄ¡C©Ð¤lªº¥¢¤õªí¥ÜµL±`¡A¤p¨à¡B¤p¤kÌ«üªº´N¬O¤@¤Á²³¥Í¡A²³¥Í³g·Ä¤±ý¤§¼Ö¡A¬°¤¿B¡B¤KW©Ò¹G´o¦Ó¤£¦Ûª¾¡A¤£ªÖצæ¾Ç¹D¡A¦òªû¡]ªøªÌ¡^¥u¦n¥H¦Ï¨®¡B³À¨®¡B¤û¨®¤Þ»¤¥LÌ¡C
¸g¨å¤ª¡G¡u¤T¬ÉµL¦w¡AµS¦p¤õ¦v¡C¡v§Ṳ́é¤é³£¥Í¬¡¦bµL±`ªº¤õ¦v¸Ì¡C¤°»ò¬O¤õ©O¡S®É¶¡¬O¤õ¡AÂàÀþ§Y³u¡F¦Ñ¤Æ¬O¤õ¡A¯d¤£¦í¬üÄRªº®eÃC¡F¯e¯f¬O¤õ¡AµL¤H¯à§K¡F·Ð´o¬O¤õ¡A¿N±o¤ßÀY¼ö´oÃø@¡FµL©ú¬O¤õ¡AµI·´§ÚÌ´¼¼zªº¤ß¥Ð¡C
¦ò¸g¸ÌÁÙ¦³¤@ӫܦnªºÄ´³ë¡G¤@ӮȤH¨«¦bÃm³¥¤¤¡A©¿µM¦Ñªê¡B¤j¶H°l¨Ó¡AµL³B¥i°k¡A¥u¦nÃkµÛ¤@±ø¾ðÃáA¶i¤J¤@¤f¤«Á×Ãø¡C¥i¬O©¹¤U¤@¬Ý¡Aµo²{¥|±ø¬r³D¥¿¦b¦R¦Þ¡A®È¤H¤ß·Q¡G¡u¨SÃö«Y¡A¥un§ìºò³oÓÃáA´N¤£·|³Q¬r³D«r¨ì¡C¡v¥¿³o»ò·Q®É¡A¬Ý¨£ÀY³»¤W¦³¤@°¦¶Â¦Ñ¹«¡B¤@°¦¥Õ¦Ñ¹«¡A¤£°±ªº«rµÛÃñø¡AȦ¹·W±i¦MÀI®É¨è¡A¤°¦»e¸Á¸¹L¡Aºw¤F¤ºw»e¤U¨Ó¡A«ê¥©ºw¦b®È¤H¤f¸Ì¡A®È¤H¤ß·Q¡G¡u¦n»¡B¦n²¢°Ú¡I¡v®È¤H«~¹ÁµÛ»eªº¬ü¨ý¡A¤@®É§Ñ°O¤F¦MÀI¡C
¬G¨Æ¸ÌªºÃm³¥¡A¦n¤ñ§Ṳ́H¥Íªº®È³~¡F¤j¶H¡B¦Ñªêªº°l³v¡AµS¦pµL±`¡A¦p¼vÀH§Î¡F¬\¤«¤¤ªº¾ðÃáA´N¹³§Ú̪º¥Í©R½u¡F¥|±ø¬r³D¥Nªí¥|¤j¡G¦a¡B¤ô¡B¤õ¡B·¡F¶Â¡B¥Õ¦Ñ¹«´N¬O¥Õ¤Ñ©M¶Â©]¡A©Ò¿×¡u¥ú³±¦ü½b¡A¤é¤ë¦p±ô¡v¡A±Þ©]®ø³u¡AºCºCªº¿i·l¾ðÃáA¿iÂ_§Ú̪º¥Í©R½u¡F¤ºw»eªí¥Ü¤±ý¡G°]¡B¦â¡B¦W¡B¹¡BºÎ¡F¤±ýªº§Ö¼Ö¡AÅý§Ú̧ѤF¦Û¨ªº¦MÀI¡A§Ñ¤F¥Í¦ºªº¹G¢¡C
¦òªû¨£²³¥Í¾D·Ð´o¤§¤õ©Ò¹G¢¦Ó¤£ª¾W¡A©ó¬O¥HºØºØ´¼¼z¡B¤è«K¡A¬°¤T¬É²³¥Í»¡Án»D¼¡B½tı¼¡BµÐÂļ¡A¦pªøªÌ¥H¤T¨®»¤¤Þ«Ä¤l¡C«Ý²³¥Í¥XÂ÷¤T¬ÉW¡A¦A¥H¦ò¼¡]¤j¥Õ¤û¨®¡^¶}¥Ü²³¥Í¡Cªk°ß¤@¼¡A¥»µL¤G¤T¡A¥u¦]²³¥Í®Ú¾÷¤£¦P¡A©ó¤@¦ò¼¡A¤è«K»¡¤T¡C
¦òªû¤]¥Î¡u¤T¨®¡v§i¶D§ÚÌ¡A¤õ¦vµL¶·®`©È¡AÁÙ¦³¤T¨®¥i¸ü§ÚÌ»·Â÷µL±`¤§¤õ¡C¤p¼¤]¦n¡A¤j¼¤]¦n¡A¦ò¼§ó¦n¡C±qÅv¼¨ì¦òªº¤@¼¹ê±Ð¡AÅý§ÚÌ¡u¦Ûı¦Û®©¡v¡AªÖ©w¦Û§Úªº¦ò©Ê¡A¤@©Àı¡A©À©Àı¡AÂà°g¦¨®©¡A¥²©w¯à¤F¥Í²æ¦º¡A«×ºÉ¤@¤Á·Ð´oµhW¡A§ä¨ì¤@Ó¤º¤ß²M²b¡B¦w꺲b¤g¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/11 ¤W¤È 06:44:13
²Ä 5047 ½g¦^À³
|
¦t©z¶¡³Ì¤jªº´I¶Q¬O¦¨¦ò (Â÷½Ñªk¬Û¡A§Y¦W½Ñ¦ò)¡K¡Kª÷è¸g
¤@©À¤§¶¡§Y¥i¦¨¦ò¡A«D¦º«á¦¨¦ò ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K
¡u¤£ÅªµØÄY¡A¤£ª¾¦ò®a¤§´I¶Q¡v¡Aì¨Ó¬O³oÓ·N«ä¡K¡K 2019/11/13 ¨Ó·½¡G¦òÁI¥Í¬¡ ©ú¥N°ª¹¬éw¤s¤j®v¤ª¡G¡u¤£Åª¡m·«ÄY¡n¡A¤£ª¾×¤ß°g®©¤§ÃöÁä¡F¤£Åª¡mªkµØ¡n¡A¤£ª¾¦p¨Ó±Ï¥@¤§W¤ß¡F¤£Åª¡mµØÄY¡n¡A¤£ª¾¦ò®a¤§´I¶Q¡C¡v¦³¹D¬O¡m·«ÄY¸g¡n§U¤H¶}®©¡A¡mªkµØ¸g¡n§U¤H¦¨¦ò¡A¨º¡mµØÄY¸g¡n©O¡H
¦ó¬°´I¶Q¡H´I¬O´I¸Î¡A´I¦³¡F¶Q¬O´I¸Î¥B¦³Åã¶Qªº¦a¦ì¡C¤£¹L²`¨s°_¨Ó¡A³o¤£¹L¬O°±¯d¦bªí±ªº´I¶Q¡C¦pªG³z¹L²{¶H¬Ý¥»½è¡A¹ï§ó¨s³ºªº¡u´I¶Q¡v¤Î¨ä²£¥Í³W«ß¡A¦ò®a¦³¡uºÖ³ø¡v³o¤@»¡ªk¡C
---- §Ú֦̾³¤Ó¦h«o¤£¦Ûª¾
¡mµØÄY¸g¡nªº¥@¬ÉÆ[¬O¡uµØÂÃ¥@¬É®ü¡v¡C¥¦§i¶D¥Í¬¡¦b®P±C¥@¬Éªº§Ú̦t©zªº¼s×À©M·L§®¡G³o¥@¬É¬O««µLºÉªº¡A§ÚÌ¿à¥H¥Í¦sªº¦a²y¦bµØÂÃ¥@¬É®ü¤¤¡A¤£¹L¬O¤@²É¹Ð®J¡A¦Ó¦b³o¹Ð®J¯ë²Ó¤pªº¦a²y¤W¡A§ÚÌ«o¯à°÷¨£¨ì¡u¤@ªá¤@¥@¬É¡A¤@¸¤@¦p¨Ó¡v¡C
¡mµØÄY¸g¡n©Ò¶}³\ªº¹Ò¬É¡A¬O¡u¤@¯uªk¬É¡v¡u¶ê¿ÄµLê¡v¡A¥¦»{¬°§Ú̳oÓ¥@¬ÉµL©Ò¿×¯Ê³´¡A§Y«K¦³¯Ê³´¤]¬O¬üªº¡C³oÓ¥@¬É¦Ü¯u¡B¦Üµ½¡B¦Ü¬ü¡A¬O¤@¯uªk¬É¡A««µLºÉ¡A¸Uªk¦Û¦p¡A³B³B¦¨¦ò¡A®É®É¦¨¹D¡C
¡mµØÄY¸g¡n¤ª¡G¡u²zµLê¡A¨ÆµLê¡A²z¨ÆµLê¡A¨Æ¨ÆµLê¡v¡AÀHµÛ¤ß¶V¨Ó¶V²MÀR¡A¥H¤Î¤£Â_©Ý®iªº¥~¦b¹Ò¬É¡A§Ú̦b®É¶¡¡BªÅ¶¡¤W¬Ý¨ì¦UºØ¨Æ³£²Å¦X©ó¯u²z¡A¦UºØ¨Æ³£¬O¦Û¦bµLꪺ¡A³Ì²×¨ì¹F¯u¹êªº¨Æ¨ÆµLêÆ[¡X¡X¤@¤Á¬Ò¦³¥i¯à¡A¤@¤Á¬Ò¤£¥i«äij¡A¤@¤Á¨Æ±¡³£¬O¯u²zªºÅã²{¡C
¤ß¶q¶V¤j¡AºÖ³ø¶V¤j
¡mµØÄY¸g¡nªº¦t©zÆ[¨ê·s¤F§Ú̪º»{ª¾¡A¥´¶}¤F§Ú̪º²´¬É¡A«äºû©M¤ß¯Ý¤]ÀH¤§¶}Áï°_¨Ó¡Aµo¤ß¼s¤j¡AºÖ³ø¤]ÀH¤§¼Wªø¡C
¡uµØÂÃ¥@¬É®ü¬OÓ¤°»ò¼Ë¤l¡H³o¬O¬s¿c¾B¨ºµLºÉªº¤jÄ@¡B¤j´d©Ò¥Í°_ªºµLÃ䪺¦]¡A³oµLÃ䪺¦]«ç»ò¥Í°_ªº©O¡Hªk©ÊµêªÅ¯à®e¸U¹Ò¡A¤ß¶q¶V¤j¡A®e¶q¤]´N¶V¤j¡C²³¥Í¤ß«Ü¤p¡AµÐÂĤ߫D±`¤j¡C¡v
³Ì¤jªº´I¶Q¬O¦¨¦ò
µØÄY¸g¡A¿ñÁ諸¥Í©R¦a¹Ï
¦òªû³QºÙ¬°¨â¨¬´L¡AºÖ³ø©M´¼¼z¬Ò¶êº¡¨ã¨¬¡A¾Ö¦³²×·¥ªº¦Û¥Ñ¡A©Ò¥H³Ì¤jªº´I¶Q¬O¦¨¦ò¡CÃö©ó¦p¦ó¦¨¦ò¡A¾ã³¡¡mµØÄY¸g¡n¬°§ÚÌ´£¨Ñ¤F®í³Óªº¤èªk¡C
ÄÀ{¦ò¦¨¦ò¹D®É»¡¡G¡u©_«v¡I©_«v¡I©_«v¡I¤@¤Á¤j¦a²³¥Í¬Ò¨ã¦p¨Ó´¼¼z¼w¬Û¡C¡v¡mµØÄY¸g¡nªÖ©w¤F²³¥Í¬O¦ò¡A¦ý³oÓ¡u¦ò¡v«üªº¬O´¼¼z¥µ¥¡A¤£¬OºÖ¼w¥µ¥¡A¦ÓºÖ¼w¤£×´N¨S¦³¡C¦òªûºÖ³øªº¶êº¡¤]¬O³q¹LµoµÐ´£¤ß¡A¨Ã¦bµL¶q§TªºµÐÂĹD¤¤¡A¼s¦æ¥¬¬I¡B«ù§Ù¡B§Ô°d¡BÁI©w¡Bºë¶i¡B´¼¼z¦Ó¨Ó¡C
ÁöµM§Ú̦b¥Í¬¡¤¤·|¸g¾úºØºØ¥Ù¬Þ¡BºØºØ¤£¥i«äijªº¥¢±æ¡A¥i¬O³Ì²×¦¨¦òªºµ²ªG¬O¥i¥H¹F¦¨ªº¡C¤£n·Q¹³§â¤@¤Á¤£¬ü¦n»°¨«¡A§ÚÌ¥u»ÝnºØ¦]©Mµ¥«Ý¡AªG²×·|¥X²{¡C³o¬O¤@ºØ³Ì¿n·¥ªºª¬ºA¡A¤]´N¬O¡mµØÄY¸g¡n©Ò»¡ªº¨âºØ¦^¦V¡A¤@ºØ¬O¦^¦V¦ò¹D¡A¤@ºØ¬O¦^¦V²³¥Í¡C
·íµo²{¥Í©Rªº²×·¥·N¸q®É¡A§ÚÌ©Ò¨«ªº¨C¤@¨B³£·|¯Ý¦³¦¨¦Ë¡A¦b·í¤U²z¸Ñ¦Û¤vªº¥Í©R¡AªY½à¤º¤ß¬Æ¦Ü¬O¥Í©Rªº¯ÊÂI¡A¤£V¨è¦Û¤v¡A¾Ç·|¤F¦Û§Ú¯¬ºÖ¡A¤£¦A¬O¤@ӯº骺²z·Q¥D¸qªÌ¡C
³o®É¡A¤£¶êº¡«ê«ê¦¨¬°§Ú̵oµÐ´£¤ßªºì¦]¡A¦¨¬°¤F§Ú̵½«Ý¤@¤Á¡A²z¸Ñ¤@¤Á¥Í©R¶Â·t©M§½ªºì¦]¡C§Ú̦]¹ï¥Í©R¼ç¯à§»Æ[ªº¬}¹î©M³]p¡A´x´¤¤F¥Í©Rªº¥D°ÊÅv¡A¦¨¬°¤F³Ì©¯ºÖªº¤H¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/1/10 ¤U¤È 02:32:58
²Ä 5046 ½g¦^À³
|
To:«Ó°¶¤j
¤£¾A¥ôªººÞ²z¶¥¼h¦p¦P°¾yÃSÃR¡A¬Oªø§ë§b·àªº³Ì¤j·~»Ù(¶Ã¤½¥¬¤£¸Ó¤½¥¬ªº¼Æ¾Ú¡A¯u¬O¸oÄ^µL¤ñ²`«¡A¤U100¼h¦aº»³£¤£¬°¹L~~~~¬Ý¬Ýªñ´ÁªÑ»ùöt¤W335ªº41X2°êX¡A¦³¤½§G¹ï·Ó²Õªº¼Æ¾Ú¶Ü?´N¬O¤£¤½§G¤£¸Ó¤½§Gªº¡AªÑ»ù¤~¯à©¹¤W°Ú!!!!)¡C§Ú̳o¨Ç³Q¢ªø§ëªÌªº¬°¤µ¤§²¤¡A¶È¦³Æ[¹î°Æ§@¥Î§C¤Î¥ÎÃÄÀW²v¬ÒÀu©ó§ù¥²ª¢¬O§_¯à¦¨¯u?¤~¯àÅý§Ú̦³¾÷·|·l¯q¨â¥¥X³õªü~~~ªüÀ±ªû¦ò¡A§Æ±æÀq§J¤jªÑªF¨ÓºÞºÞ³o¨Ç°¾yÃSÃR¡A§O¦AÅý¥L̶÷d¤F.... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/10 ¤W¤È 08:04:28
²Ä 5045 ½g¦^À³
|
³Q¢ªø§ë,§Y«D³Q¢ªø§ë,¬O¦W³Q¢ªø§ë!
¬Û¬O¦³,Åé©ÊªÅ¡A¦WºÙ¦Ó¤w!
---------------------------------------
¦ò¸g¤Wªº¤£¡BµL¡BªÅ¡B«Dµ¥¦b§_©w¤U¦C¯S©Ê,
(1)¤£ÅÜ©Ê (2)¥D®_©Ê (3)³æ¤@©Ê
¦b»¡©úÅé©Ê(¥»Åé/ªk©Ê)¬OµL¦Û©Ê,©ÎºÙªÅ©Ê/©ÊªÅ/ªÅ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/1/9 ¤U¤È 07:14:00
²Ä 5044 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/9 ¤U¤È 03:33:37
²Ä 5043 ½g¦^À³
|
¤@¤Á½Ñ¦ò¬Ò±qª÷è¸g¥X¡C
n²`¤J¤F¸ÑªÌ¡A¥i¤Wºô¦Û¤v°Ñ®©¡G²bªÅªk®v©ÒÁ¿¸Ñªºª÷è¸gºën¡C«D±`ºë±m¡C ¦³¼v¤ù¤Î¤å¦r¡A¦@800¦h¶°¡A¨C¶°¼Æ¤ÀÄÁ
www.amtb.tw/#/videoplay?menuidparent=29&menuidchild=513&voice=&mp4=1&numbers=316293
⋯⋯⋯ ª÷è¸gªº´¼¨¥¼z»y¡X¦p¦ó¥Í¬¡¦b¨s³º¶êº¡´¼¼z¤§¤¤¡@¡@¡]²Ä¤@¶°¡^¡@¡@1995/5¡@¡@·s¥[©Y¦ò±Ð©~¤hªL¡]¸`¿ý¦Ûª÷è¯ëY¬ã²ß³ø§i09-023-0001¶°¡^¡@¡@ÀɦW¡G29-513-0001 ¡@¡@¡mª÷è¯ëY¡n¬O¾ãÓ¤jÂøgªººën¡A¦Óµo°_¦b¬ï¦ç¦Y¶º¡A¤JªÙ½Ã¤j«°¤^¹¡A³o¼Ëµo°_ªº¡A³oӥηN«D±`¤§¡C¥@´Lªíºtµ¹§Ú̬ݡA¦Ü°ªµL¤Wªº¦òªk¡A¨s³º¶êº¡ªº´¼¼z¡A´N¦b§Ṳ́é±`¥Í¬¡¤§¤¤¡A¨S¦³Â÷¶}¥Í¬¡¡C´«¥y¸Ü»¡¡A¦¿©~¤h¬°§ÚÌÂI¯}¡A¾Ç¦ò¾Ç¤°»ò¡H¦òµÐÂĥͬ¡¦b¨s³º¶êº¡´¼¼z¤§¤¤¡Aªíºtµ¹§Ú̬ݡC§Ṳ́Z¤Ò«Ü¥i¼¦¡A¤@¤Ñ¨ì±ß¥Í¬¡¦b¦k·Q¡B·Ð´o¤§¤¤¡AW¤£³ô¨¥¡C§ÚÌn¾Ç¦ò¡A¦p¦ó§â§Ú̱q¦k·Q¡B·Ð´oªº¥Í¬¡¸Ì±¬ð¯}¡A¤]nÀò±o¹³½Ñ¦ò¦p¨Ó¡B¹³¤jµÐÂĤ@¼Ë¡A¥Í¬¡¦b¨s³º¶êº¡´¼¼z¤§¤¤¡A³o¤~±o¨ì¯u¹êªº¨ü¥Î¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/9 ¤U¤È 03:16:31
²Ä 5042 ½g¦^À³
|
ª÷è¸g
ªø§ë¡Gªø§ë¤§¬Û §Y«Dªø§ë¡G¨ÃµLªø§ë¤§¹ê¬Û¡A¥¦¬OªÅµL¦Û©Ê ¬O¦Wªø§ë¡G¼È¥BºÙ¥¦¬°ªø§ë¡C
¦ò»¡¥@¬É¡A§Y«D¥@¬É¡A§Y¦W¥@¬É¡C¡]ª÷è¸g¤¤¦³«Ü¦h¦p¦¹¸g¥y¡^
§Y«DXx¡G¦bÁ¿ªk©Ê§YªÅµL¦Û©Ê |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2022/1/9 ¤U¤È 01:16:05
²Ä 5041 ½g¦^À³
|
ª÷è¸g¬O¤H¥Í´¼¼z¶}±Òªº¥²Åª¸g¨å¡A ¦ý... ªø§ë¡B§Y«Dªø§ë¡B¬O¦Wªø§ë¡I §Ú¯º¤F...«¢«¢«¢«¢ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/9 ¤W¤È 07:24:07
²Ä 5040 ½g¦^À³
|
m.youtube.com/watch?v=_gveT-SqjrE
ª÷è¸gªº¤Q¤j¸g¥y¡A°ª¹¬ºë¸Ñ(¦@约10¤ÀÄÁ)
¨C¥y¬Ò¯àÅý±z®©¤J¦p¨Ó¯u¹ê¸q¡I(©ú¤ß¨£©Ê)
§U衆¥Í§ä¦^¥»¦³ªº¦ò©Ê¡C
¤Z©Ò¦³¬Û¬Ò¬O虚¦k¡BY¨£½Ñ¬Û«D¬Û¡A«h¨£¦p¨Ó¡I ¤@¤Á¦³¬°ªk¦p¹Ú¤Ûªw¼v¡B¦pÅS¥ç¦p¹q¡BÀ³°µ¦p¬OÆ[¡I
¬Ý¯}¡B©ñ¤U¡B¦Û¦b¡I
¦p¹Ú¡B¦p¤Û¡Bªø§ë¡I
ªø§ë¡B§Y«Dªø§ë¡B¬O¦Wªø§ë¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/6 ¤W¤È 11:39:18
²Ä 5039 ½g¦^À³
|
Ӯ׬ã¨s:
¾AÀ³µý:ºC©ÊC«¬¨xª¢/Off Label of PV
BÃĪººn¥Ø¼Ð¤§¤@¬OPegasysªºÂà´«.
¦³¦h¤Ö¬O PV¥ÎªÌ¤£ª¾?
----------------------------
www.roche.com/dam/jcr:3bf6408c-c282-404a-af1d-ea85f41ea704/en/inv-update-2016-04-19-e.pdf
2016¦~Q1¬ü°ê¾P°â11¦Ê¸U¬ü¤¸ 11,000,000¬ü¤¸/(12,00*0.6¥Ø«e»ù®æ)=1527¤H-©u
¹s°â»ù: 4000¬ü¤¸/4°w(¨C¶g¤@°w) ¨C©u:12,000¤¸ ¤½¥q¥X³f»ù:°²³]¬°¹s°â»ùªº60%
www.goodrx.com/coupon?drug_id=32363&pharmacy_id=31240&quantity=4&extras=AvJrrfanxl8Aeoy00Cj4KIKz3gY%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%3D&price_tab=coupons&
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/5 ¤U¤È 07:50:33
²Ä 5038 ½g¦^À³
|
Adbry(Tralokinumab) vs Dupilumab (¤T´ÁÁ{§É¸ê®Æ ,16¶gªvÀø,¤G¶g¤@°w300mg, PK)
12%/36%=38% 23%/32%=72%
Tralokinumab ªº¤T´Á--¥Dn«ü¼ÐÀø®Ä2 : EASI75 ¸g¹ï·Ó²Õ½Õ¾ã¬°Dupilumab
Dupilumab Àø®Ä¬OTralokinumabªº 1.38~2.63¿.
ASLAN004 1b EASI75 ©M¹ï·Ó²Õ®t²§37%(50%-13%=37% ¦b²Ä8¶g),©MDupilumab (32%~36%)¬Ûªñ
----------------------------------------------------------- ¤@.Adbry(Tralokinumab)
The proportion of patients who achieved EASI-75 at week 16:
ECZTRA 1: 25% vs 13% for placebo (®t²§ 12%); ECZTRA 2: 33% vs 10% for placebo (®t²§ 23%);
¤G.Dupilumab The proportion of patients who achieved EASI-75 at week 16:
SOLO 1: 51% vs 15% for placebo (®t²§36%) SOLO 2: 44% vs 12% for placebo ;(®t²§32%)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis www.nejm.org/doi/full/10.1056/nejmoa1610020
¤T.ASLAN004, 1b , The proportion of patients who achieved EASI-75 ²Ä8¶g
1b : 50% vs 13% for placebo (®t²§37%)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/5 ¤U¤È 03:03:05
²Ä 5037 ½g¦^À³
|
Adbry(Tralokinumab) vs Dupilumab (¤T´ÁÁ{§É¸ê®Æ ,16¶gªvÀø,¤G¶g¤@°w300mg, PK)
9%/28%=32% 12%/28%=42%
Tralokinumab ªº¤T´Á¥Dn«ü¼ÐÀø®Ä :IGA 0,1 ¸g¹ï·Ó²Õ½Õ¾ã¬°Dupilumab 32%~42%
Dupilumab Àø®Ä¬OTralokinumabªº2.3~3.1 ¿.
¤@.Adbry(Tralokinumab) The proportion of patients who achieved an IGA score of 0 or 1 at week 16:
ECZTRA 1: 16% vs 7% for placebo (®t²§9%) ECZTRA 2: 21% vs 9% for placebo (®t²§12%);
¤G.Dupilumab The proportion of patients who achieved an IGA score of 0 or 1 at week 16:
SOLO 1: 38% vs 10% for placebo (®t²§28%) SOLO 2: 36% vs 8% for placebo ;(®t²§28%)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis www.nejm.org/doi/full/10.1056/nejmoa1610020
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/1/5 ¤U¤È 02:18:56
²Ä 5036 ½g¦^À³
|
¿³Âd41X2-°êX¤µ¤Ñ1400¸Ñª¼,§¹¥þ¸Ñª¼¦¨¥\,¸r¼}...,¤]´¿¸g§ë¸ê¹L¥¦,¦ý¤¤¶¡Â÷¶}¤F,¦p¤µ¬Ý¥¦¦¨¥\,¤ß¤¤´À¥¦Ä±±o¶}¤ß¤]¦Ê·P¥æ¶°, ³Ì«á§Æ±æ¤j®a»P¦Û¤v¦b¦Ñ·àªº§ë¸ê¯à¸Ñ®M§Y¥i~~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/1/5 ¤W¤È 09:47:12
²Ä 5035 ½g¦^À³
|
December 28, 2021 Adbry Approved for Moderate to Severe Atopic Dermatitis
The approval was based on data from 3 pivotal, randomized, double-blind, placebo-controlled phase 3 (ECZTRA 1-3) trials that evaluated the safety and efficacy of Adbry in 1934 adults with moderate to severe AD. ECZTRA 1 (ClinicalTrials.gov Identifier: NCT03131648) and
ECZTRA 2 (ClinicalTrials.gov Identifier: NCT03160885) assessed Adbry as monotherapy for 52 weeks.
ECZTRA 3 (ClinicalTrials.gov Identifier: NCT03363854) assessed Adbry in combination with topical corticosteroids in adults for 32 weeks. ( ¥[ Ãþ©T¾J )
In all 3 trials, patients were randomly assigned to receive Adbry 600mg subcutaneously on Day 0, then 300mg every other week or placebo for 16 weeks. The primary endpoints for all trials were an Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) at week 16 and at least a 75% improvement in the Eczema Area and Severity Index (EASI) score at week 16.
Key secondary endpoint was the reduction of weekly average Worst Daily Pruritus Numeric Rating Scale (NRS) of at least 4 points on the 11-point itch NRS.
Results from all 3 trials showed that a significantly greater proportion of patients treated with Adbry met the primary and secondary endpoints at week 16 compared with placebo.
The proportion of patients who achieved an IGA score of 0 or 1 at week 16:
ECZTRA 1: 16% vs 7% for placebo (difference from placebo 9%; 95% CI, 4-13); ECZTRA 2: 21% vs 9% for placebo (difference from placebo 12%; 95% CI, 7-17); ECZTRA 3: 38% vs 27% for placebo (difference from placebo 11%; 95% CI, 1-21).
The proportion of patients who achieved EASI-75 at week 16:
ECZTRA 1: 25% vs 13% for placebo (difference from placebo 12%; 95% CI, 6-18); ECZTRA 2: 33% vs 10% for placebo (difference from placebo 22%; 95% CI, 17-28); ECZTRA 3: 56% vs 37% for placebo (difference from placebo 20%; 95% CI, 9-30).
The proportion of patients who achieved at least a 4-point reduction in the weekly average Worst Daily Pruritus NRS at week 16:
ECZTRA 1: 20% vs 10% for placebo (difference from placebo 10%; 95% CI, 4-15); ECZTRA 2: 25% vs 9% for placebo (difference from placebo 16%; 95% CI, 11-21); ECZTRA 3: 46% vs 35% for placebo (difference from placebo 11%; 95% CI, 1-22).
www.empr.com/home/news/adbry-approved-for-moderate-to-severe-atopic-dermatitis
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/5 ¤W¤È 08:27:53
²Ä 5034 ½g¦^À³
|
adbry. ¬¡©Ê¦¨¤À¡GTralokinumab ¯e¯f¡G¯SÀ³©Ê¥Öª¢ ®pȾP°â¦ôp¡G2027¦~ªº16»õ¬ü¤¸ §åã¡G12¤ë28¤é ¤½¥q¡GLeo Pharma
¤c¤l¡G´îºCÂÄ¿Õµá©M¹p¥Íª«´Óª«ªº¹«§À¯f±wªÌªº¯SÀ³©Ê¥Öª¢¬O¤@Ó°ª¤jªº¯´§Ç¡A¦ý¤¦³ÁªºLeo Pharma·Ç³Æ±N¨ä»PAdbry¤@°_±µ¨ü¡A³o¬O±Mªù°w¹ïIL-13²ÓM¦]¤lªº°ß¤@§å㪺ªvÀø¤èªk¡C¸ÓÃĥΩó±w¦³¤¤«×¦ÜÄY«ªºÀã¯lªº±wªÌ¡A¥L̤£·|±q§½³¡ÀøªkÀò±o¥R¤Àªº½w¸Ñ¡C Astrazeneca³Ìªì¬°ý³Ý¶}µo¡A2016¦~¥H¨C¦~1.15»õ¬ü¤¸ªº»ùȬ°Leo¾P°â¹ïLeoªº«Ý¹J¡C¥¦¤»¤ë¥ÑU.K.©M¼Ú·ùªººÊºÞ¾÷ºc§åã¡C GlobalDataªº¤ÀªR®v»{¬°¡A2027¦~ªºMed¾P°âÃB¥i¯à¹F¨ì16»õ¬ü¤¸¡C¤´µM¡A¥æ¤e¸ÕÅç¤ñ¸û¦³§Q©óÀÀ¿³¤½¥qªº®ÄªG¡A¨ä¤¤2020¦~²£¥Í¶W¹L40»õ¬ü¤¸ªº¾P°âÃB¡A¤µ¦~°l踪60»õ¬ü¤¸¡C Dupixent©MAdbry«Ü§Ö´N¯à±q½÷·çªº¤fªAªvÀøCibinQo±Á{Ävª§¡C ¡]¬ü°ê©|¥¼®Öã¡A¦w¥þ©Ê°ÝÃD¥d¦í¡^ Eli LillyªºAtopic¥Öª¢Ô¿ïlebrikizumab-¨ä¤¤¯S²§©Ê¹v¦VIL-13²ÓM¦]¤l - ¬O¦b²Ä3´Á´ú¸Õ¤¤¡C
Adbry Active ingredient: tralokinumab Disease: atopic dermatitis Peak sales estimate: $1.6 billion in 2027 Approved: Dec. 28 Company: Leo Pharma
The scoop: Slowing the roll of Sanofi and Regeneron¡¦s Dupixent in atopic dermatitis is a tall order, but Leo Pharma of Denmark is ready to take it on with Adbry, the only approved treatment that specifically targets the IL-13 cytokine. The drug is for patients with moderate-to-severe eczema who don¡¦t get adequate relief from topical therapies. Originally developed for asthma, AstraZeneca sold the treatment to Leo for $115 million in 2016. It was approved by regulators in the U.K. and European Union in June. Analysts at GlobalData see the med¡¦s sales potentially reaching $1.6 billion in 2027. Still, cross-trial comparisons favor the efficacy of Dupixent, which generated sales of more than $4 billion in 2020 and is on track to approach $6 billion this year. Dupixent and Adbry could soon face competition from Pfizer¡¦s oral treatment Cibinqo. Eli Lilly¡¦s atopic dermatitis candidate lebrikizumab¡Xwhich also specifically targets the IL-13 cytokine¡Xis in phase 3 testing.
www.fiercepharma.com/special-report/2021-s-new-drug-approvals-adbry
It won¡¦t be the only challenger to Dupixent in the coming years however. The market leader could see additional competition from other drugs, including Eli Lilly/Almirall¡¦s IL-13 inhibitor lebrikizumab, which has just reported positive top-line phase 3 results in the Adhere study and is heading for regulatory filings next year.
Some analysts think the biggest challenge could come from Pfizer¡¦s JAK1 inhibitor Cibinqo (abrocitinib), which has shown impressive data in phase 3 trials and has the advantage of oral dosing ¡V but could be held back by concerns about the safety of the JAK class.
Pfizer has run a head-to-head trial of abrocitinib versus Dupixent to try to show superior efficacy, with top-line results pointing to better results on symptoms including itch and skin clearance.
Cibinqo has already been approved in the UK,EU and Japan, with an FDA decision delayed by a review of the JAK class and its potential to cause cardiovascular side effects.
It¡¦s not the first JAK inhibitor to get a green light for atopic dermatitis however, as Lilly¡¦s Olumiant (baricitinib) and AbbVie¡¦s Rinvoq (upadacitinib) both beat it to market and Rinvoq also has head-to-head data showing improvement over Dupixent.
µM¦Ó¡A¥¦¤£·|¦¨¬°¥¼¨Ó´X¦~°ß¤@¤@Ó¬D¾ÔªÌ¡C¥«³õ»â¾ÉªÌ¥i¥H¬Ý¨ì¨ä¥L¬r«~ªºÃB¥~Ävª§¡A¥]¬AEli Lilly / AlmirallªºIL-13§í»s¾¯Lebrakizumab¡Aèè³ø§i¤F¿n·¥ªº³»¯Å²Ä3¶¥¬q¡A¦b©ú¦~ªº¥Ó½Ð¬ã¨s¤¤¾ÉPºÊºÞ¥Ó½Ð¡C
¤@¨Ç¤ÀªR®v»{¬°³Ì¤jªº¬D¾Ô¥i¯à¨Ó¦Û½÷·çªºJAK1§í»s¾¯Cibinqo¡]Abrocitinib¡^¡A³o¦b²Ä3¶¥¬q¸ÕÅ礤Åã¥Ü¤F¥O¤H¦L¶H²`¨èªº¼Æ¾Ú¡A¨Ã¥B¨ã¦³¤fµÄµ¹ÃĪºÀu¶Õ - ¦ý¥i¥H³q¹L¹ïJak½Òµ{ªº¦w¥þªº¾á¼~¨Óªý¤î¡C
½÷·ç¤½¥q¤w¸g¹B¦æ¤FAbrocitinibªºÀY¸£«e¸ÕÅç»PDupixent¶i¦æ¤F¨ô¶VªºÀø®Ä¡A³»½uµ²ªG«ü¦V¯gª¬¡A¥]¬Aæ±Äo©M¥Ö½§¶¡»Øªº¯gª¬§ó¦nªºµ²ªG¡C
CibinQO¤w¸g¦b^°ê¡A¼Ú·ù©M¤é¥»§åã¡A³q¹L¼f¬d¶®¥[¶¥¼h¤Î¨ä¾ÉP¤ß¦åºÞ°Æ§@¥Îªº¼ç¤O©µ¿ð¤FFDA¨M©w¡C
¥¦¤£¬O²Ä¤@Ó¬°¯SÀ³©Ê¥Öª¢Àò±oºñ¿Oªºjak§í»s¾¯¡A¦]¬°²ú²úªºoleumiant¡]baricitinib¡^©Mabbvieªºrinvoq¡]upadacitinib¡^À»±Ñ¥¦¨ì¥«³õ¡ARinvoq¤]¦³ÀY¨ìÀY¼Æ¾Ú¡AÅã¥Ü¥X¹ïDupixentªº§ïµ½¡C pharmaphorum.com/news/leo-puts-target-on-dupixent-in-us-as-fda-clears-tralokinumab/
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/5 ¤W¤È 06:26:42
²Ä 5033 ½g¦^À³
|
¥xÁÞ¤j¡A
ASLAN004 ªº¬ãµoªÌ¨Ó¦Û¿D¬wªºCSL¡A·íµM¥À°ê©ñ6Ó¦¬®×¤¤¤ß¡A约¦û6/59. ¬ü°ê¥¿¨üOmicron¨C¤é¦Ê¸U½T¶E,¦¬®×¤]§Ö¤£°_¨Ó¡C ¤j®a³£¤@¼Ë¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K LEO Pharma «Å¥¬ FDA §åã Adbry™¡]tralokinumab¡^§@¬°²Ä¤@Ó¤]¬O°ß¤@¤@Ó±Mªù°w¹ï¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢¦¨¤Hªº IL-13 ªvÀø Adbry ¬O LEO Pharma ¦b¬ü°ê±À¥XªººÓ¥Íª«»s¾¯¡A¹wp±N©ó 2022 ¦~ 2 ¤ë¦bÃÄ©±¤W¥«¡C
Tralokinumab ¦b¬ü°ê¥H¥~¥H Adtralza® ªº°Ó«~¦W¾P°â¡A¥Ø«e¤w¦b¼Ú·ù¡B^°ê¡B¥[®³¤j©Mªü©Ô§BÁp¦X©ªø°êÀò±o§åã¡C
¤¦³Á¤Ú°Ç¾|´¶¡A2021 ¦~ 12 ¤ë 28 ¤é ¡V Âå¾Ç¥Ö½§¯f¾Ç»â°ìªº¥þ²y»â¾ÉªÌ LEO Pharma A/S ¤µ¤Ñ«Å¥¬¡A¬ü°ê¹«~©MÃĪ«ºÞ²z§½ (FDA) ¤w§åã Adbry™¡]tralokinumab¡^¥Î©óªvÀø¤¤«×¦Ü««×18 ·³©Î 18 ·³¥H¤Wªº¦¨¦~¤Hªº¯SÀ³©Ê¥Öª¢¡A¨ä¯e¯f¤£¯à³q¹L§½³¡³B¤èÀøªk±o¨ì¥R¤À±±¨î¡A©ÎªÌ·í³o¨ÇÀøªk¤£¥i¨ú®É¡C Adbry ¥i¥H»P©Î¤£»P§½³¡¥Ö½èÃþ©T¾J¤@°_¨Ï¥Î¡C1 Adbry ¬O²Ä¤@Ó¤]¬O°ß¤@¤@ÓÀò±o FDA §å㪺¥Íª«»s¾¯¡A¥¦¯S²§©Êµ²¦X¨Ö§í¨î IL-13 ²ÓM¦]¤l¡AIL-13 ²ÓM¦]¤l¬O¯SÀ³©Ê¥Öª¢Åé¼x©M¯gª¬ªºÃöÁäÅX°Ê¦]¯À¡C1,2,3 ¡§¤µ¤Ñ FDA §åã Adbry ¹ï LEO Pharma ©M¼Æ¦Ê¸U±w¦³¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ªº¤H¨Ó»¡¬O¤@Ó«nªº¨½µ{¸O¡A¥LÌ¥¿¦b§V¤O¬°³oºØºC©Ê©Mµê®zªº¯e¯f´M§ä¦X¾AªºªvÀø¤è®×¡A¡¨º®u°]°È©x Anders Kronborg »¡¡C LEO Pharma A/S ªº©xû©M¥N²zº®u°õ¦æ©x¡C ¡§§@¬°§Ú̦b¬ü°êªº²Ä¤@ӥͪ«»s¾¯¡AAdbry ¼Ð»xµÛ§Ú̦b±À¶iÂå¾Ç¥Ö½§¯f¾ÇÅ@²z¼Ð·Çªº¨Ï©R¤¤¨ú±o¤F«n¶i®i¡C¡¨
Adbry ªº§åã¬O°ò©ó ECZTRA 1¡B2 ©M ECZTRA 3 ÃöÁä 3 ´Á¸ÕÅ窺¦w¥þ©Ê©M¦³®Ä©Êµ²ªG¡A¨ä¤¤¥]¬Aªñ 2,000 ¦W±w¦³¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ªº¦¨¦~±wªÌ¡C 1 ¦w¥þ©Ê¼Æ¾Ú¬O±q¤Ó¶°¦X¤¤µû¦ôªºÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¸ÕÅç¡A¥]¬A ECZTRA 1¡B2 ©M ECZTRA 3¡B¾¯¶q±´¯Á¸ÕÅç©M¬Ì]¤ÏÀ³¸ÕÅç¡C 1
¡§¯SÀ³©Ê¥Öª¢¥i¯à«ÜÄY«¥B¤£¥i¹w´ú¡A³o¤£¶È¹ï±wªÌ¹ê²{ªø´Á¯e¯f±±¨î¨ã¦³¬D¾Ô©Ê¡A¦Ó¥B¹ïÁ{§ÉÂå¥ÍªºªvÀø¤]¨ã¦³¬D¾Ô©Ê¡A¦]¬°³oºØÁc«ªººC©Ê¥Ö½§¯fªºªvÀø¿ï¾Ü¦³¡A¡¨³ì¯Ç´Ë¡P¦èº¸¥±§B®æ»¡¡A MD¡BPhD¡BMPH¡A³ìªvµØ²±¹y¤j¾ÇÂå¾Ç»P°·±d¬ì¾Ç¾Ç°|¥Ö½§¯f¾Ç°Æ±Ð±Â¡Atralokinumab Á{§É¸ÕÅç¬ã¨sû¡C ¡§§@¬°¤@ºØ±Mªù°w¹ï©M¤¤©M IL-13 ²ÓM¦]¤lªºªvÀø¤èªk¡AAdbry ±N¦¨¬°§Ú̪vÀø³]³Æªº«n¸É¥R¡A±q¦ÓÀ°§U±wªÌ±±¨î¯SÀ³©Ê¥Öª¢¡¨
Adbry ±N´£¨Ñ 150 mg/mL ¹w¸Ëª`®g¾¹¡A¥Î©ó¥Ö¤Uª`®g¡Aªì©l¾¯¶q¬° 600 mg¡AÀH«á¨C¹j¤@©Pª`®g 300 mg¡C Adbry ¥i¥H»P©Î¤£»P TCS ¤@°_¨Ï¥Î¡C1 ¹ï©ó 100 ¤½¤ç¥H¤Uªº±wªÌ¡A¦pªG¦bªvÀø 16 ¶g«á¥Ö½§Åܱo²M´·©Î´X¥G²M´·¡A¥i¥H¦Ò¼{¨C 4 ¶gªA¥Î 300 ²@§J¾¯¶q¡C1
¬°¤FÀ°§U²Å¦X±ø¥óªº±wªÌ¨Ï¥Î Adbry¡ALEO Pharma ±N±À¥X Adbry™ Advocate™ p¹º¡A¥H¤ä«ù¬ü°ê±wªÌªº¶EÂ_©M Adbry ªvÀø¡C
¡§¹ï©ó±w¦³¯SÀ³©Ê¥Öª¢ªº¤H¨Ó»¡¡A³oºØ¸g¾ú¶W¶V¤F¥Ö½§¡A³q±`·|¼vÅT¥L̥ͬ¡¤¤«nªº¤ß²zªÀ·|¤è±¡A¡¨¥þ°êÀã¯l¨ó·|Á`µôݺ®u°õ¦æ©x¦¶²ú¡P¥¬¬¥§J»¡¡C ¡§«Ü°ª¿³¬°±w¦³¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ªº¦¨¦~±wªÌ¬Ý¨ì¤@ºØ·sªº¡B¦³°w¹ï©ÊªºªvÀø¿ï¾Ü¡C¹³³o¼ËªºªvÀø¶i®i¬°¨º¨Ç¥i¯àªá¤F¼Æ¦~®É¶¡§V¤O´M§ä¦X¾AªºªvÀø¤èªk¨Ó´î»´³oºØ¯e¯ft¾áªº¤H´£¨Ñ¤F«æ»Ýªº§Æ±æ¡C¡¨
FDA ªº§åã¼Ð»xµÛ tralokinumab ©ó 2021 ¦~Àò±o²Ä¤¦¸¥þ²yºÊºÞ§åã¡C Tralokinumab ¦b¬ü°ê¹Ò¥~¥H Adtralza ® ªº°Ó«~¦W¾P°â¡A¥Ø«e¤w¦b¼Ú·ù¡B^°ê¡B¥[®³¤j©Mªü©Ô§BÁp¦X©ªø°êÀò±o§åã¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/1/4 ¤U¤È 11:06:07
²Ä 5032 ½g¦^À³
|
Lebrikizumab¤T´ÁÁ{§É¤w¹F¼Ð Tralokinumabªñ´Á¤wÀò¬ü°êFDA®Öã¤W¥«¡A »â¥ýLebrikizumab ASLAN 004ªº°ÝÃD¦b¦¬®×¡A±`³Q¬Ì±¡¨Ó·o¶Ã¡A·Q¤£³q¬°¦ó¤£¦b¬Ì±¡¬Û¹ïéwªº¥xÆW¶}³]¦¬®×Âå°|¡A«À£¿D¬w¹J¨ì¬Ì±¡¤jÃzµo¡A ¥u³Ñ·s¥[©Y¯Ã¦èÄõ¬Ì±¡ÁÙºâéw¡A¥i¥H¥ý±q³o¨âÓ°ê®a¥ý¦¬®×¡A¨ì¥Ø«eÁÙ¨S¦³¬Ý¨ì¤½¥q¤½§i ¥l¶Ò²Ä¤@¦ì¦¬®×ªº¸ê°T¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/4 ¤U¤È 01:11:25
²Ä 5031 ½g¦^À³
|
5¡A¨Ì·Ó¤Wz¤GÃÄÀø®Ä¹ïÀ³ªº¾P°â·~ÁZ¦ôºâ ASLAN004¦bADªº¥þ²y¾P°âÀ³¥i¹F34»õ¬ü¤¸¡A ¥t¥~¥[ý³Ý¡þCOPD⋯⋯¡A¾AÀ³¯g¡A
¦ôp34/55%=62»õ¬ü¤¸¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/4 ¤U¤È 12:58:37
²Ä 5030 ½g¦^À³
|
3.Lebrikizumab Àø®Ä¦ô¬°DUPILUMAB 75%
2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q.
Out-License and Other Agreements Almirall Agreement
·í®ÉAlmire CEO ºÙ Lebrikizumab ¦b¼Ú¬w°Ï AD ¥«³õ¥i¾P»õ¬ü¤¸. ´«ºâ¥þ²y25»õ¬ü¤¸.
MOA : Lebrikizumab ±µ¦X IL13 ªºB¡BCÁ³±Û , ¦ýIL13 & IL-13R£\1 ¤´¥i±µ¦X¡A¥u¬OµLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II«¬ ¨üÅé ¦]Lebrikizumab , IL13 & IL-13R£\1 ¤´¥i±µ¦X¦û¾Ú IL-13R £\1, ¼vÅT0~50% IL4 °T¸¹¶Ç»¼¡C ¤]¸ÑÄÀ Lebrikizumab ¤G´ÁÁ{§É¹w«á¥Dn«ü¼Ð»P¹ï·Ó²Õ¤ñ È ¥u¦³Dupilumab ¬ù75%¡C
4.Lebrikizumab©MTralokinumab ¦U°µ§¹ý³Ý/COPD ¤T´ÁÁ{§É,µ²ªG¬Ò¥¼¦¨¥\.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/4 ¤U¤È 12:44:33
²Ä 5029 ½g¦^À³
|
1.ASLAN004 MOA ¦PDUPILUMAB , ¤w³Qµý©ú¥i¦P®ÉªýÂ_IL4/IL13
©Ò¥HASLAN004 Àø®Ä¤j©óµ¥©óDUPILUMAB ¼Ð·ÇÀøªk,¤£¥i¯à¤ñDUPILUMAB ®t.
2. Adtralza (tralokinumab)ªºÀø®Ä¶Èdupilumab ADªº50%,¼Ú¬wÃĵý¤wÀò±o LEO ºÙ,¥¼¨Ó¥þ²y¥i¾P16»õ¬ü¤¸.
MOA :
Tralokinumab ±µ¦XIL13 ªºA¡BDÁ³±Û ¨Ï IL13 & IL-13R£\1 µLªk±µ¦X¡A¤]µLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II «¬¨üÅé
¶ÈªýÂ_IL13,µLªkªýÂ_IL4
¥H¤W¸ÑÄÀ Tralokinumab ¤T´ÁÁ{§É¹w«á«ü¼Ð¡AÀø®Ä´X¥G¥u¦³Dupilumab 50%¡C
------ remapconsulting.com/blockbuster-drugs-of-the-next-decade/
ªü¯S©Ô¤ã¡]¯S©Ô¬¥°ò§V°¨¥¬¡^ Adtralza ©ó 2021 ¦~ 6 ¤ëÀò±o EMA §åã¡A¥Î©óªvÀø¦¨¤H±wªÌ¤¤«×¦Ü««×¯S²§©Ê¥Öª¢¡A³o¨Ç±wªÌ¬O¥þ¨ªvÀøªºÔ¿ïªÌ¡C¥¿¦b¦V¬ü°ê¹«~©MÃĪ«ºÞ²z§½¡]FDA¡^©M¥þ²y¨ä¥L½Ã¥Í·í§½´£¥æ§ó¦hºÊºÞÀÉ¡C¸ÓÃĪ«¤w¸g¶}µo¡A±N¥ÑLEO»sÃĤ½¥q¾P°â¡A³o¬O¥Ö½§¬ì»â°ì³Ì±j¤jªº°Ñ»PªÌ¤§¤@¡CAdtralzaªº§åã¬O°ò©óECZTRA 1¡A2©M3ÃöÁ䶥¬q3¸ÕÅ窺Àø®Ä©M¦w¥þµ²ªG¡A¨ä¤¤¥]¬A1¡A900¦h¦W¦¨¤H±wªÌ¤¤«×¦Ü««×¥Öª¢9¡C ¸ÓÃĪ«¦b16©PªºªvÀø¤¤ªí²{¥XÀu©ó¦w¼¢¾¯ªºÀu¶V©Ê¡A¦b¦hÓµ²ªG±¹¬I¤Ï¬M¯S²§©Ê¥Öª¢10ªº¸ñ¶H©MÄpª¬¡C¹wp¨ì2027¦~¡AAdtralzaªº¾P°âÃB±N¹F¨ì16»õ¬ü¤¸
7. Adtralza (tralokinumab) Adtralza was approved in June 2021 by the EMA for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. Additional regulatory filings are underway with the US FDA and other health authorities worldwide. The drug has been developed and will be marketed by LEO Pharma, one of the strongest players in the field of dermatology. Adtralza¡¦s approval was based on efficacy and safety results from the ECZTRA 1,2 and 3 pivotal Phase 3 trials, which included more than 1,900 adult patients with moderate-to-severe dermatitis9. The drug demonstrated superiority over placebo during 16 weeks of treatment across multiple outcome measures reflecting the signs and symptoms of atopic dermatitis10. Adtralza is projected to generate $1.6 billion in sales by 2027. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥¼¨Ó10138795 |
µoªí®É¶¡:2022/1/4 ¤U¤È 12:09:45
²Ä 5028 ½g¦^À³
|
½Ð¯q¤Ñ©R¤j¤Îª©¤Wªº¦U¦ì¹F¤H
Yasln004 (°²³]°Æ§@¥Î¤ñ¸û§Cªº±¡ªp¤U) Àø®Ä¬Û·íDupilumabªº¤Q¦¨ ¨º±z¦ôaslnªÑ»ù ´ÝȳѦh¤Ö? Àø®Ä¥u¦³Dupilumabªº¤K¦¨ ¨º±z¦ôaslnªÑ»ù ´ÝȳѦh¤Ö? Àø®Ä¥u¦³Dupilumabªº¤»¦¨ ¨º±z¦ôaslnªÑ»ù ´ÝȳѦh¤Ö? Àø®Ä¥u¦³Dupilumabªº¥|¦¨ ¨º±z¦ôaslnªÑ»ù ´ÝȳѦh¤Ö?
Åwªï¤j®a¨Ó°Q½×!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/1/4 ¤W¤È 08:32:09
²Ä 5027 ½g¦^À³
|
Y¦~©³±ÂÅv¡B³Q¦¬Áʧ@·~¥¿¦b½Í§P¶i¦æ®É ¨ä¹êý³Ý´Á¤¤³ø§i¤]¥X¨Ó¤F(¨È·à±d¯uªº¦³¦bºâ®É¶¡ÂI) ³Q¦¬ÁÊ»ù©¹¤W´£¤É~~~
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/1/3 ¤U¤È 12:49:03
²Ä 5026 ½g¦^À³
|
·PÁ¤ѩR¤j¤Î¦U¦ì¤j¤j¤À¨É
§Æ±æ2022·|¬O½Â઺¤@¦~ ·sªº¤@¦~·|º¥¤J¨Î¹Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/1 ¤U¤È 02:32:02
²Ä 5025 ½g¦^À³
|
µÐ´£¦Û©Ê(¤ß)¥»¦Û²M²b¡B¨ã¨¬¡B¤£°Ê·n¡A¯à¥Í¸Uªk¡I
¦ý¥Î¦¹¦Û©Ê(¤ß)ª½¤F¦¨¦ò¡I(¤»¯ªÁIªkºën)
(¦]¬Û¬Ò虚¦k¡AÅé©ÊªÅ±I¡A¤T¤ß¤£¥i±o¡A ©Ò±o¤§¬ÛªÅ¡A¯à±o¤§¤ß¥çªÅ¡A¥ç¤£¦íªÅ¡A ¬GÀ³随®É¦w¦í©óµL©Ò¦í¤ß¡A¦Ó¦æ©ó¥¬¬I¡A ¼©Ê°_סAª½¨ì¦¨¦ò)
µL¬Û¤£¦í¬Û µL©À¤£¦í©À ¿ô®É¥²µL¼~ ²M²b¦ÛµL¾l
¦]µL©Ò±o¬G¡AµL¦³®£©Æ¡]¤ß¸g¡^ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/1 ¤U¤È 02:17:13
²Ä 5024 ½g¦^À³
|
2.FB825:ÀR¯ßª`®g/1¤ë¤@°w(¦X¤@/LEO):5»õ¬üª÷ ---------(²Ä¤@¥NIgE§í¨î¾¯³Ý³ß·ç¼Ö ® á´¹ª`®g¾¯ 150 ²@§J ½Ã¸pµß¬Ì¿é¦r²Ä 000835 ¸¹ Xolair ¶·«öÅ髤ÎIgE°tÃÄ,¥Ø«e¬Oý³Ý³Ì«á¤@½u, AD Á{§É没¦¨¥\) ¥Ñ±ÂÅvª÷®t 5.3»õ¬ü¤¸,¶È°ê»Ú¦æ±¡1/2~1/3,
www1.ndmctsgh.edu.tw/pharm/pic/medinsert/005XOL01.pdf
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GJCY10146705 |
µoªí®É¶¡:2022/1/1 ¤U¤È 01:08:56
²Ä 5023 ½g¦^À³
|
½Ð±Ð¤Ñ©R¤j
FB825¸òASLN004³£¬O¤@Ó¤ë¤@°w ©Ò¥H¬Q¤Ñ§Q¥Î°²¤éµy«á¤ñ¸û¤@¤U¨âªÌ FB825¬Oªý¤î¤U´åªºIgE¥Í¦¨¡AASLN004¬O±q¤W´å§í¨îIL-4¤ÎIL-13
¦X¤@©xºôQ&A¦³´£¨ì¡u¥Ø«e¥xÆW«ü¼Ð±´¯ÁÁ{§É¸ÕÅ窺Àø®ÄÁͶաA»P¥ý«e¤w§¹¦¨ªº12¤Hªø´Á±´¯Á¸ÕÅçµ²ªG¬Û·í¡A§Y¨Ï²Å¦XÀ³µª«ü¼Ð¤H¼Æ¬°64%¡A¾ãÅéÁ{§ÉÀø®Ä¤´¯à»PDupixent¤Ç¼Ä¡C¬ü°ê¦¬®×¯f±w¤¤¡A°ª¹F94%¯f±w¦b«ü¼Ð½d³ò¤º¡A¦]¦¹§Ú̹ï¬ü°ê¸ÕÅ窺¾ãÅé®ÄªG¦³«H¤ß¡C¡v ³o¬qµ¥©ó¬O»¡ÁöµMFB825¥u®ø·À¤U´åªºIgE¡A¦ýÀø®Ä¤£¿é§í¨î¤W´åIL-4¤ÎIL-13ªºDupixent¡C ¤Ñ©R¤j«ç»ò¬ÝFB825³oÀø®Äµ{«×?±qMOA¨Ó¬Ý¡A§í¨î¤W´åIL-4¤ÎIL-13ªºDupixent¤ÎASLN004¬O§_À³¸Ó¤ñFB825§ó¦³®Ä¤~¹ï?
¥t¥~¡A¦X¤@©xºôQ&A¤]´£¨ìFB825¥´ºâ±qÀR¯ßª`®g§ï¦¨¥Ö¤Uª`®g¡A¡u¦X¤@¤w¸g¨Æ¥ý§¹¦¨µû¦ô¡A½T»{¨âºØ¾¯«¬ªº¥Íª«¥i§Q¥Î²v¬Ûªñ¡C¡v Á{§É¶i«×¤W¡AFB825¤]¥uºC¤F´XÓ¤ë¡A§ÚÓ¤H«Ü¾á¤ßASLN004ªºÀu¶Õ¤@¤@³Q°l¤W¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/12/31 ¤U¤È 10:16:07
²Ä 5022 ½g¦^À³
|
¨È·à±d2021¹L¤FªêÀY³D§Àªº¤@¦~ §Æ±æ2022¬O¨È·à±d¾Ä°_ªºÂà§é¦~ ¦U¦ì·à¤Í·s¦~·s§Æ±æ Happy new year
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/12/29 ¤U¤È 05:18:40
²Ä 5021 ½g¦^À³
|
investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2021-financial-and-operating
EYLEA 2021¦~«e¤T©u¾P°â67»õ¬ü¤¸,¦~¦¨ªø21%. ¦ô¤µ¦~¾P93~94»õ¬ü¤¸
2011¦~11¤ë¤W¥«,¤w¤W¥«²Ä10¦~.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/12/29 ¤U¤È 04:07:57
²Ä 5020 ½g¦^À³
|
¦pªGASLAN004ªºÃĮĵ¥©óDupilumab¡A ASLAN004ªºÀu¶Õ¦³ 1.°Æ§@¥ÎµL结½¤ª¢¡AÀu©óDupilumab 2.ÃĪ««O¦sÀu©óDupilumab 3.¥|¶g¤@°w¦¨¥\²v«D±`¤j¡AÀW²vÀu©óDupilumab¡C «OÀI¤½¥q·|«Øij¿ïþ¤@ºØ¥ý¥Î???«Ü²M·¡. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/12/29 ¤U¤È 02:58:39
²Ä 5019 ½g¦^À³
|
1¡BEylea»ù®æ¡]¥Ø«e»ù®æ¡^¡A¨C¤G¤ë¤@°w 40 mg/mL Eylea intravitreal solution from $1,940.90 for 0.05 milliliters Quantity Per unit Price 0.05 milliliters $38,818.00 $1,940.
¦~1940¬ü¤¸X6¡×11640¬ü¤¸¡]¨C¦~¶O¥Î¡^
2¡BLucentis»ù®æ¡]¨C¤ë¤@°w¡^ 6 mg/mL Lucentis intravitreal solution from $1,230.98 for 0.05 milliliters Quantity Per unit Price 0.05 milliliters $24,619.60 $1,230.98
12x1230=14760¬ü¤¸¡A¨C¦~¶O¥Î
¤@¤@¤@¤@¤@¤@¤@¤@ Lucentis¶O¥Î¤ñEylea¶Q3000¬ü¤¸¡A¨C¦~¡A²´·ú¨C¦~¦h¥´6¦¸°w¡A³o¼ËÁÙ¯à¦~¾P4l»õ¬üª÷¡C
¥¼¨ÓAslan004¦~¾P°â¡A¥i¯à©MDupilumab ¬Û·íªº©w»ù¡A¦Óµ²½¤ª¢§C©ÎµL¡AÄvª§¤O¬Û¹ï°ª¡C ¾P°âÃB¦ôupilumab110»õ¬ü¤¸¤@¥b¡A¯uªº§C¦ô¤F¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/12/29 ¤U¤È 02:34:47
²Ä 5018 ½g¦^À³
|
¬Ý¤@¤UAMD¥«³õ²Ä¤G¦WªºLucentis¡]2006¦~¤W¥«¡^ ¦b2019¦~¤´¦³²Ä¤@¦WEylea¡]2011¦~¤W¥«¡^ªº¬ù¤@¥b¾P°âª÷ÃB¡C 41»õ¬ü¤¸vs78»õ¬ü¤¸ ¥«³õ°÷¤j¡A¤@ª½¦b¦¨ªø¡C´N«Ü¦³»ù»ù
AD¥¼¨Ó240»õ¬ü¤¸ªº¥Íª«»s¾¯¥«³õ¡A¥Ø«e¤~60»õ¬ü¤¸¡C
ASLAN004 vs dupilumab ±ø¥óÀu©óLucentis vs Eylea ¡A¤j®a©ñ¤ß¡I
¤@¤@¤@¤@¤@
¥þ²y¾P°âª÷ÃB¡]»õ¬üª÷) PK ¡X- A:Lucentis) //B:(Eylea)**B/A**¦XpA+B 2006(¤W¥«//) 2009¡V20.35//¡]Eylea 11¤ë FDA ®Öã¤W¥«) 2012¡V24.00//8.70**B/A=36%**32.7 --------(Eylea²Ä¤@¦~¾P°â, ¦~«×¶O¥Î16,000¬ü¤¸¨C2Ӥ르¤@°w vs Lu centis 24000¬ü¤¸/¨C¤ë¤@°w) 2013¡V39.53//20.43**B/A=51%**50.96 ¡]2013/10¤ë¡A¤ÀªR®v¦ô2018/Eylea 47»õ¬ü¤¸) 2014¡V43.00//28.00**B/A=65%**71 2015¡V34.00//40.8.00**B/A=120%**74.8 (Lucentis ¡¥s ¥é¥ÍÃĦL«×¤W¥«//Eylea ¤W¥«²Ä¥|¦~,¦~¾P°â¶W¹LLucentis)) 2016¡V33.00//55.38**B/A=161%**88.38 2017¡V33.00//62.82**B/A=190%**95.82 2018¡V37.00//67.00**B/A=181%**104 2019¡V41(¦ô)//78.52**B/A=191%**119
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- AMD¡X¡X°w¾¯ Ävª§¥v¡]ªvÀø¡X²´·ú¶À¯Z³¡¯fÅÜ¡^ ¤@¡BLucentis¡]Ranibizumab¡^¡X¡X2006¦~6¤ë¡AFDA®Öã¤W¥«,ù¤ó(¬ü°ê¾P°â)/¿ÕµØ(¨ä¥L¦a°Ï¾P°â) ¡A¨C¤ë¤@°w¡A¨C¦~24,000¬ü¤¸Àøµ{¶O¥Î
¤G¡BEylea¡]aflibercept¡^¡X¡X-2011¦~11¤ë,FDA®Öã¤W¥«¡ARegeneron Pharmaceuticals(¬ü°ê¾P°â)/«ô¦Õ(¨ä¥L¦a°Ï¾P°â,§Q¼í§¡¤À)¡A¨C2¤ë¤@°w¡A¨C¦~16,000¬ü¤¸Àøµ{¶O¥Î¡C
Lucentis¡]Ranibizumab¡^ ©MEylea¡]aflibercept¡^ ¬O¥Ø«e¼sªx¥Î©ó²´¬ì¯e¯fªºÀøªk¡AªvÀø¥]¬A·s¥Í¦åºÞ¡]Àã©Ê¡^¦~ÄÖ¬ÛÃö©Ê¶À´³ÅÜ©Ê¡Bµøºô½¤ÀR¯ßªý¶ë«á¶À´³¤ô¸~¡B¿}§¿¯f©Ê¶À´³¤ô¸~¡]DME¡^©MDME¦ñ¦³¿}§¿¯f©Êµøºô½¤¯fÅÜ¡C
¨âªÌ§¡¬°§Ü¦åºÞ¤º¥Ö¥Íªø¦]¤l¡]VEGF¡^Àøªk¡C2018¦~¡A³o¨â´ÚÃĪ«ªº¥þ²y¾P°âÃB±µªñ110»õ¬ü¤¸¡A¶È¦b¬ü°êªº¾P°âÃB´N¶W¹L¤F58»õ¬ü¤¸¡C Lucentis¦b¬ü°êªº±M§Q±N©ó2020¦~¨ì´Á¡A¦ý¹w´ú2021¦~¾P°âÃB¤´±N¹F¨ì41»õ¬ü¤¸¡C 2015¦~²Ä¤@Ó¥é¥ÍÃÄ¡A¦L«×¤W¥« 75%»ù®æ¡C Eyleaªº¤@¶µÃöÁä±M§Q¦b¬ü°ê±N©ó2023¦~¨ì´Á¡A¦b¼Ú¬w¨ì2025¦~¤~¨ì´Á¡A¹wp2021¦~¾P°âÃB±N¹F¨ì70»õ¬ü¤¸¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/12/29 ¤U¤È 01:38:14
²Ä 5017 ½g¦^À³
|
ÁöµM¬O¦Ñ¥Í±`½Í¡A¦ý³o¤]¬O¤ä¼µ·à¤Í Ä~Äò¨«¤U¥hªº«H©À |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/12/29 ¤U¤È 12:46:14
²Ä 5016 ½g¦^À³
|
§¹¥þ¦P·N¡A©t¨àÃĤjªº¬Ýªk¡C
¯à©M¥¼¨ÓÀ禬110»õ¬ü¤¸ªº¥@¬ö¤jÃÄdupilumab¡AÀø®Ä¬Û·í°Æ§@¥Î§C¡A¤w«D±`¤£®e©ö¡C
⋯¨âÃĪº¾÷¨îMOA³Ì«á¬Ò¬Û¦P¡A¦P®ÉªýÂ_IL4/IL13°T¸¹¶Ç»¼¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2021/12/29 ¤U¤È 12:13:28
²Ä 5015 ½g¦^À³
|
¦b³oºØCEOªºªv²z¤U,ÄÝ©ó2019«e¶i³õªº¦Ñ·à¤ÍÌ,¯uªº¨¯W¤F,¤×¨ä¬O°ª»ù¶R¶iªº,¥Ñ°J§Æ±æ¤j®a¯à¸Ñ®M,ÁöµM§Ú»{¬°004ªºÃĮĤ£·|¤ñ¦n§ù¥²ª¢¦h¤Ö,¦ý¤O«÷°Æ§@¥Î§C©ó§ù¥²ª¢ªº½æÂI,¬Ý¯à§_¬ð³ò¦Ó¥X¤F~~¦ý§ó§Æ±æ¶^¯}§Úªº²´Ãè,©Ò¦³ªº¼Æ¾Ú³£¤ñ§Ú·Q¹³ªº§ó¦n~~~~
¦Ü©ó·s·à¤Í´N¦Û¦æ§PÂ_¦p¦ó¶i³õ¤F~~§Æ±æ©¯¹B°Á{¤j®a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/12/29 ¤W¤È 09:35:33
²Ä 5014 ½g¦^À³
|
À³µL©Ò¦í¦Ó¥Í¨ä¤ß¡C
ª¾©ö¦æÃø¡I
¥²¥ý¤F®©缘°_©ÊªÅ¤§¯u²z¡C
¤è¯à¥H¨ÆפߡC
004 2b Á{§É295¤H¡A预¦ô4-5Ó¤ë¯à¦¬®×§¹¦¨¡C
¬°¶Ò¤T´Á4-6»õ¬ü¤¸资ª÷¡A¦ôp8¬ü¤¸/ªÑ¬O¬ü°ê¨é°Óªº»{¦P»ù¡A¥´8§é¡A6.4¬ü¤¸/ªÑ¡A¥]¾P¬O2023¦~ªìªº»ù®æ¡C
¦b¦¹¤§«e·|±ÂÅv«D¬ü°Ï¡C
¬üªÑªÑ©Ê¡A¤@»ù¨ì¦ì¡A¤@«Å¥¬³Q¨ÖÁÊ¡AASLNªº§ë¸ê´N¹F³Ì终结ªG¡C
资ª÷2023¦~¥½¬ÒµL°ÝÃD¡C
ªø§ëªÌ´NµL¤ß¡AµL¦í¡AµL©À¡AµL¬Û¨ÓÆ[·Ó¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/12/29 ¤W¤È 08:52:59
²Ä 5013 ½g¦^À³
|
¶i«×¤W¬Ý¤]¨S¦³·N¸q¤F¡A½Ö¬O§ó¾A¦XªºCEO ¤]¬OÓ°ÝÃD ¦^Âk¨ì®Ö¤ß»ùÈ¡AÃĪºÁ{§É¼Æ¾Ú¥i¯à ¤ñ¸û¹ê¦b |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/12/29 ¤W¤È 08:23:19
²Ä 5012 ½g¦^À³
|
»â¾ÉªÌ¤U¥xÀ³¸Ó«ÜÃø¡A¥u¯à´Á«ÝÃĦn¼Æ¾Ú¦n |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2021/12/29 ¤W¤È 08:13:25
²Ä 5011 ½g¦^À³
|
To:ª©¥D:½ÐÀ°¦£±N¼ÐÃD§ï¬°¥H¤U~~~¤j·PÁÂ
¡§004±Ò°Ê¬D¾Ô§ù¥²ª¢ªº2BÁ{§É¸ÕÅç¡AªÑ»ù¤£¶R³æ¡A·Q«¥Í¥u¦³Åý¤£¾A¥ôªº»â¾ÉªÌ¤U¥x¡¨
¼Ð´£ªø«×³Ì¦h¶È¯à¦p¦¹¡CBY¥²´Iºôª©¥D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/12/28 ¤U¤È 09:51:39
²Ä 5010 ½g¦^À³
|
©ú¤Ñ¹L«á¤j¤j¡A µê¤ß½Ð±Ð¡A¬°¤°»ò§Aı±o¼Æ¾Ú¤£¦n¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2021/12/28 ¤U¤È 02:03:43
²Ä 5009 ½g¦^À³
|
To:ª©¥D:½ÐÀ°¦£±N¼ÐÃD§ï¬°¥H¤U~~~·P®¦
¡§ASLN004·sÃıҰʬD¾ÔDupilumabªº2BÁ{§É¸ÕÅç¡A¦ý¤£¹ïªº»â¾É¶¥¼hÅýªÑ»ù©e©}¡A·Q¯D¤õ«¥Í¥u¦³Åý¤£¾A¥ôªº»â¾ÉªÌ¤U¥x¡¨
¼ÐÃD¹Lªø¡AµLªk§ó§ï¡A½Ð¦A×¥¿¡C BY¥²´Iºôª©¥D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/12/28 ¤U¤È 01:43:58
²Ä 5008 ½g¦^À³
|
¥H¤U¬O2021/9/29¸Ñª¼¨ì¤µ¤Ñªº¬Ýªk.... ¥»¤H1´Á¸Ñª¼¤j¶^·í¤Ñ¬å¥X»ù¦ì2¶ô5¥ª¥k!!¨ì¤µ¤Ñ¤S¶^¨ì1¶ô¿ú¤W¤U~²{¦bªºªÑ»ù¤w¸gÅçÃÒ·í®Éªº¬Ýªk~ ¤§«áÁÙ·|©¹0.8¾aªñ~¤£«H¶Ü ? ½Ð±µµÛ¬Ý !! ºô¸ô°g´öªGµMÁÙ¬O·|¨R©ü¤@°ï¤H°Ú~½Ð¦Û¤v¤p¤ß!!
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/23 ¤U¤È 05:55:34²Ä 4784 ½g¦^À³ ¬Q¤é«ùÄò¤j¶^7%¤¤~«Ü¼y©¯¥»¤H¦b¨È·à±d¬ü¤Æªº1´Á¸Ñª¼¼Æ¾Ú..¦ý¥«³õ¤£»{¦P¤j¶^«á...¦b2¶ô¦h´N¥þ¼Æ¥X²æ.. ¤§«e¤w¸g»¡¹LªGµM¤j¶^«áÁÙ·|«ùÄò³Ð·s§C...¥¼¨Ó±NºCºC½w¶^¨ì¤@¶ô¤§¤U..¤d¸U¤£n¤£¬Û«H ?
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/15 ¤U¤È 07:49:46²Ä 4750 ½g¦^À³ ¥H¤U§ó¥¿¬°004 ¤j®aÁÙ°O±o¶Ü¡H ¨È·à±d³£¬O¤@³eªº§@·¡A¤§«eÁx¹DÀù¤T´Á¥¼¸Ñª¼¤§«e¤]¬O³£«Ü¼ÖÆ[¡AµM«á³oÃ䪺ºô¤Í±M·~¤ÀªR¤å³¹³sµo¡I»¡¦³¦h¼F®`¤@©w·|¹L¤T´Á¡Aµ²ªG¤@¸Ñª¼¥¢±ÑªÑ»ù¤j¶^¡A³oÃ䪺ªº°l±·¤å³¹ÃÒ¾Ú¤]³£¤@°_¬å±¼¤F¡AµM«á²{¦b¦A¨ÓÓ004¡K ¬Ý¦ü«Ü±M·~¼Æ¾Ú¤å³¹Ä~Äò°l±·¡A¦ý¨Æ¹ê004´N¬O¼Æ¾Ú¤£¦n¡AÃø¤£¦¨¨gµo¬Ý¦ü±M·~ªº¤å³¹¡A¨È·à±d´N·|ùL¤G´Á¶Ü¡HµM«á³Q¦¬ÁÊ¡H ·í§½ªÌ°g¡A®ÇÆ[ªÌ²M¡A½Ð¤T«ä¡K
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/12 ¤U¤È 03:24:19²Ä 4709 ½g¦^À³ Ó¤Hı±o³o¦¸¤£¬OÀ£§C¥X³f¸ÑŪ, ¦U¦ì¦³¬Ý¹L¼Æ¾ÚÀu¦ý¬OªÑ»ù¶^±¼¤@¥bªºªº¨Ò¤l¶Ü? ³q±`¼Æ¾ÚÀu³£¬Oº¦¤@¿!¤£·|À£§CÅý§A¦Y³fªº©Ô! ¨S·N¥~ªÑ»ù·|½w¶^¨ì1¶ô¤§¤U~
¥H¤U¬O9¤ë©³ªº¬Ýªk¦Ü¤µ¤£ÅÜ...½w¶^¨ì§A¤ß·W·N¶Ã...
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤W¤È 08:53:03²Ä 4663 ½g¦^À³ ¥H¤U¬O 9/29 ªº¬Ýªk ¦Ü¤µ¤£ÅÜ
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/9/29 ¤W¤È 09:06:30²Ä 4559 ½g¦^À³ ¬Û«H¶R¨È·à±dªº¦U¦ì¤j¤j,¥¼¶}¼ú¤§«e³£¦bÀqÀq½Lºâ,§Úªº¦Ê¸U§ë¸ê¦b¤E¤ë¸Ñª¼«á·|½¦¨¦n´X¿·Ç³Æ¶R¨®¶R©Ð¤F,¦ý³o¦¸¶}¼úµ²ªG´N¬O¤£¦p¹w´Á,§Ú¥i¥H§i¶D¦U¦ì°ê¥~¦U§ë¸ê¶R®a¹Î¶¤¬O¤£¶R³æªº,¤]¤£n¬Û«H±Ë»ò§ë¸ê¾÷ºcµ¹¥Ø¼Ð»ù8¶ô¿ú(³o¨Ç³£¬O½æªÅªº¦nªB¤Í,§Aªº¿ú³£¬O³Q³o¨Ç½æªÅªÌÁȨ«)! °ê¥~ªº§ë¸ê¹Î¶¤¤£¬Oªxªx¤§½ú,I«á¬ã¨s¹Î¶¤ªº¥\¤O¤£ª¾¹D±j¹L³oÓª©ªº¬Y¨Ç¤ÀªR¼Æ¦Ê¿!¤]¤£·|¸ò§AºtÀ¸..¦n¼Æ¾Ú´N¬O¤j¶R,Äê¼Æ¾Ú´N¬O¤j½æ! ¦pªG¯uªº¹Ú¿ô¤F´NÅý¥L¿ô§a,¤d¸U¤£n¨I¾K¦b¹Ú¸Ìn¶}©l¾Ç·|±¹ï²{¹ê ! ¬üªÑºD©Ê¦pªG¤j¶^«áªº¹j¤ÑÁÙ¬O¤j¶^,¤§«áªº¼Æ©P±N·|«ù³Ð·s§C,¤£«H¶Ü ?11¤ë1¤é¤j®a¨ÓÅçÃÒ !
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤U¤È 02:49:51²Ä 4668 ½g¦^À³ ¥«³õ¤W°µÃþ¦üªºÃįuªº¤Ó¦h¤F~³Ìªñ1¦~¨Ó¦³´X®a¬Û¦PÃĪ«1´Á¸Ñª¼«á³£¤jº¦5¦¨~1¿¥H¤W,¦ý¥u¦³¨È·à±d¦V¤U¶^±¼¤@¥bªÑ»ù¥H¤W, ¦pªG¯uªº¦p³oÓªO¤W¤ÀªRªº¼Æ¾Ú¨º»ò¦n,ªÑ»ù¬°¦óÁÙ¬O«®À??Ãø¹D¬O¨º¨Ç§ë¸ê¾÷ºc¥þ³¡¬Ý¨«²´½M¤F¤£±¤¦¨¥»¤@¸ô¨g½æ? ¨Æ¹ê¬O¨È·à±dªº¼Æ¾Ú´N¬O®t©ó¹w´Á,¤§«á¤]¤£·|¦³±Ë»ò¤H·|¨Ó½Í±ÂÅv©Î¬O¨ÖÁÊ,ªÑ»ù±N·|½L¶^¨ì1¶ô¿ú¥H¤U....
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤W¤È 08:53:03²Ä 4663 ½g¦^À³ ¥H¤U¬O 9/29 ªº¬Ýªk ¦Ü¤µ¤£ÅÜ
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/9/29 ¤W¤È 09:06:30²Ä 4559 ½g¦^À³ ¬Û«H¶R¨È·à±dªº¦U¦ì¤j¤j,¥¼¶}¼ú¤§«e³£¦bÀqÀq½Lºâ,§Úªº¦Ê¸U§ë¸ê¦b¤E¤ë¸Ñª¼«á·|½¦¨¦n´X¿·Ç³Æ¶R¨®¶R©Ð¤F,¦ý³o¦¸¶}¼úµ²ªG´N¬O¤£¦p¹w´Á,§Ú¥i¥H§i¶D¦U¦ì°ê¥~¦U§ë¸ê¶R®a¹Î¶¤¬O¤£¶R³æªº,¤]¤£n¬Û«H±Ë»ò§ë¸ê¾÷ºcµ¹¥Ø¼Ð»ù8¶ô¿ú(³o¨Ç³£¬O½æªÅªº¦nªB¤Í,§Aªº¿ú³£¬O³Q³o¨Ç½æªÅªÌÁȨ«)! °ê¥~ªº§ë¸ê¹Î¶¤¤£¬Oªxªx¤§½ú,I«á¬ã¨s¹Î¶¤ªº¥\¤O¤£ª¾¹D±j¹L³oÓª©ªº¬Y¨Ç¤ÀªR¼Æ¦Ê¿!¤]¤£·|¸ò§AºtÀ¸..¦n¼Æ¾Ú´N¬O¤j¶R,Äê¼Æ¾Ú´N¬O¤j½æ! ¦pªG¯uªº¹Ú¿ô¤F´NÅý¥L¿ô§a,¤d¸U¤£n¨I¾K¦b¹Ú¸Ìn¶}©l¾Ç·|±¹ï²{¹ê ! ¬üªÑºD©Ê¦pªG¤j¶^«áªº¹j¤ÑÁÙ¬O¤j¶^,¤§«áªº¼Æ©P±N·|«ù³Ð·s§C,¤£«H¶Ü ?11¤ë1¤é¤j®a¨ÓÅçÃÒ ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2021/12/28 ¤W¤È 09:00:32
²Ä 5007 ½g¦^À³
|
¿Ë·Rªºª©¥D:½ÐÀ°¦£±N¼ÐÃD§ï¬°¥H¤U~~~
ASLN004·sÃıҰʬD¾ÔDupilumabªº2BÁ{§É¸ÕÅç¡A¦ý¤£¹ïªº»â¾É¶¥¼hÅýªÑ»ù©e©}¡A·Q¯D¤õ«¥Í¥u¦³Åý¤£¾A¥ôªº»â¾ÉªÌ¤U¥x |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/12/28 ¤W¤È 08:45:55
²Ä 5006 ½g¦^À³
|
¬Ý¨ì²{¦bªº»ù¦ì¤S¶}©l¤âÄo¤F¡A½Ö¨ÓÀ°§Ú§â¤â¸j°_¨Ó |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2021/12/28 ¤W¤È 06:58:03
²Ä 5005 ½g¦^À³
|
©ú¤Ñ¹L«á¤j¤j¡A§A¹ï ¨È·à±d©¹¶^¯}1¤¸¬üª÷ÁÚ¶i
²{¦b»¡¤°»ò³£¨S¥Î¡A¥u¦³µ¥.... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2021/12/25 ¤W¤È 09:27:50
²Ä 5004 ½g¦^À³
|
°ò¥»¥\¡]¤¤¤å¡^ www.tsim.org.tw/journal/jour29-6/02.PDF |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/12/22 ¤W¤È 10:09:13
²Ä 5003 ½g¦^À³
|
ÅÞ¿è«ä¦ÒÃD¡G~~~¸É¥R ©ú¦~©³¸òÃļt½Í±ÂÅv®É¡AASLAN004ªºÃĮġB¦w¥þ©Ê¡Kµ¥¡A¨È·à±d³£·|¸ò¸ÓÃļt»¡©ú¡C ¦pªG±z¬O¸ÓÃļt¡A±zª¾¹DASLAN004ªºÃĮġB¦w¥þ©Ê¡Kµ¥³£¤j(µ¥)©óDupilumab¡A ±z¬OÃļt¡A±z«Ü²M·¡Dupilumab¤w¸g¬O2022¦~¥þ²y¤Q¤jºZ¾PÃĪ«¡C ±zÁÙ¥ÌÄ@¥u·Q³Q±ÂÅv???ÅÞ¿è«Ü©Ç¡C¤£¦¬Áʨȷà±d??? (·|½Í±ÂÅv¡A¥Nªí¨È·à±d¦Û¤vª¾¹DASLAN004ªº2bÁ{§É¸Ñª¼¥¿¦V) (ÁÙ¦³IQVIA Biotech¥Xªº2bÁ{§É¸Ñª¼¼Æ¾Ú³ø§iI®Ñ)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/12/22 ¤W¤È 09:47:43
²Ä 5002 ½g¦^À³
|
ÅÞ¿è«ä¦ÒÃD¡G ©ú¦~©³¸òÃļt½Í±ÂÅv®É¡AASLAN004ªºÃĮġB¦w¥þ©Ê¡Kµ¥¡A¨È·à±d³£·|¸ò¸ÓÃļt»¡©ú¡C¦pªG±z¬O¸ÓÃļt¡A ±zª¾¹DASLAN004ªºÃĮġB¦w¥þ©Ê¡Kµ¥³£¤j(µ¥)©óDupilumab¡A ±z¬OÃļt¡A±z«Ü²M·¡Dupilumab¤w¸g¬O2022¦~¥þ²y¤Q¤jºZ¾PÃĪ«¡C±zÁÙ¥ÌÄ@¥u·Q³Q±ÂÅv???ÅÞ¿è«Ü©Ç¡C¤£¦¬Áʨȷà±d??? (·|½Í±ÂÅv¡A¥Nªí¨È·à±d¦Û¤vª¾¹DASLAN004ªº2bÁ{§É¸Ñª¼¥¿¦V)
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
´£¿ô¦U¦ì¤j¤j¡A ¦pªG©ú¦~©³¡A±ÂÅv¡B¥¿¦V¸Ñª¼´¦ÅS®É¶¡¦³©µ¿ðªº¸Ü¡A¤£¥Î¾á¤ß¡C¦]¬°¦b¡§½Í§P¡¨¤F¡A¦U¦ì¤j¤j½Ð@¤ßµ¥Ô¨Îµ¡C
¤w¸g¦³2021¦~12¤ë14¤é¤U±¸ê°T¡G ½÷·ç¦P·N¥H 67»õ¬ü¤¸¦¬Áʬü°ê¥Í§Þ¤½¥q Arena Pharmaceuticals¡A´«ºâ¨CªÑ¦¬Áʳø»ù¬° 100¬ü¤¸ªº®ø®§ (¼vÅT¬ü°ê300¸U¤HªººC©Êª¢Äp©Ê¸z¯f) (³Ì°ª¾P°âÃB¥i¹F25»õ¬ü¤¸) (Àø®Ä±N¤ñ Bristol Myers Squibb(BMY-US) (¦Ê®É¬ü¬I¶QÄ_)ÃļtºX¤Uªº Zeposia §ó¦³®Ä)¡K¡K¡C
¦¬Áʨȷà±dª÷ÃB¡A§Ú³£»{¬°À³¸Ón¶W¹L67»õ¬ü¤¸¡C(ÁÙ¨Sºâý³Ý¡BASLAN003¡K¡K)½Ð°Ý¦U¦ì¤j¤j¦³²§Ä³¶Ü??
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2021/12/21 ¤U¤È 06:52:42
²Ä 5001 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/12/21 ¤U¤È 05:43:18
²Ä 5000 ½g¦^À³
|
¬ÝÀ´¼v¤ù¤~¬Oªø§ë°ò¥»¥\, ¡X¡X×¥¿
ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
2.Dupilumab MOA -¼v¤ù
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
MOA www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¤@¡BII«¬¨üÅé(TYPE II RECEPTER): ¡X¡X¹L±Ó©Êµoª¢¤ÏÀ³ ¸ô®|:
¤»Ó¥D¨¤: °tÅé : (1)IL-4(¤¶¥Õ¯À4¸¹) ,(2)IL-13 (¤¶¥Õ¯À13¸¹) ¨ü¾¹ : (3)IL-4R£\ , (4)IL-13 R£\1 (5)II«¬¨üÅé (TYPE II RECEPTER): (²Õ¦¨ A : IL4 ±µ¦XIL-4R£\ ¦A±µ¦X IL-13 R£\1) (²Õ¦¨ B : IL13 ±µ¦XIL-13R£\1 ¦A±µ¦X IL-4 R£\)
(6)pSTAT6
1. IL-4¤ÎIL-13 ¬Ò¥i ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³ , ¦³¥H¤UA¡BB¨â±ø¸ô®|
A: ¥ÑIL-4 ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¸ô®|
¸ô®|(1). IL-4 ±µ¦X IL-4R£\ = IL4& IL-4R£\ (2). IL4& IL-4R£\ ¦A±µ¦X IL-13 R£\1=II «¬¨üÅé (²Õ¦¨II«¬ ¨üÅé) (3). II «¬¨üÅé±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼ (4). ¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6) (signal transducer and activator of transcription 6, pSTAT6) ¶Ç¾É¸ô®|, (5) ¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
B: ¥ÑIL-13 ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¸ô®|
¸ô®|(1). IL-13 ±µ¦X IL-13R£\1 = IL13& IL-13R£\1 (2). IL13 & IL-13R£\1 ¦A±µ¦X IL-4 R£\= II«¬ ¨üÅé (²Õ¦¨II «¬¨üÅé) (3). II «¬¨üÅé ±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼ (4). ¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6) (signal transducer and activator of transcription 6, pSTAT6) ¶Ç¾É¸ô®|, (5) ¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¤G丶Dupilumab¤ÎASLAN004 ¬Ò¥i¦P®ÉªýÂ_IL4¤ÎIL13 °T®§¶Ç¾É¸ô®|
Dupilumab µ²¦XIL-4R£\ & ASLAN004 µ²¦XIL-13 R£\1¤§¾÷Âà(MOA) ¬Ò¥i¦P®ÉªýÂ_ II«¬¨üÅ餧²Õ¦¨¦ÓÁקKÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6)¤§¬¡¤Æ¡A¤]ÁקK¹L±Ó©Êµoª¢¤ÏÀ³. ¨Ï±oA&B ¸ô®|¤¤¤£²£¥Í(2)~(5)¸ô®|¡C
¤T¡BLebrikizumab & Tralokinumab M〇A , ¥u¯àªýÂ_IL13 °T¸¹¶Ç»¼¡AµLªk§¹¥þªýÂ_IL4 °T¸¹¶Ç»¼¡A¥\¯à¤j´î75%~50%¡C
µLªkªýÂ_ A¸ô®| (2): IL4 & IL-4R£\ ¦A±µ¦XIL-13R£\1 , ²Õ¦¨ªºII«¬¨üÅé, ¦]¦Ó±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼¡A¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (signal transducer and activator of transcription 6, STAT6) ¶Ç¾É¸ô®|,¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
¥u¯àªýÂ_B¸ô®| : Lebrikizumab ±µ¦X IL13 ªºB¡BCÁ³±Û , ¦ýIL13 & IL-13R£\1 ¤´¥i±µ¦X¡A¥u¬OµLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II«¬ ¨üÅé Tralokinumab ±µ¦XIL13 ªºA¡BDÁ³±Û ¨Ï IL13 & IL-13R£\1 µLªk±µ¦X¡A¤]µLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II «¬¨üÅé
¥H¤W¸ÑÄÀ Tralokinumab ¤T´ÁÁ{§É¹w«á«ü¼Ð¡AÀø®Ä´X¥G¥u¦³Dupilumab 50%¡C
¦]Lebrikizumab , IL13 & IL-13R£\1 ¤´¥i±µ¦X¦û¾Ú IL-13R £\1, ¼vÅT0~50% IL4 °T¸¹¶Ç»¼¡C ¤]¸ÑÄÀ Lebrikizumab ¤G´ÁÁ{§É¹w«á¥Dn«ü¼Ð»P¹ï·Ó²Õ¤ñ È ¥u¦³Dupilumab 50%~75% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/12/21 ¤U¤È 05:23:12
²Ä 4999 ½g¦^À³
|
------Ó¤H¬Ýªk
1.ASLN004(2b):¥Ö¤Uª`®g/¤@¤ë¤@°w ----(¥i¦P®É®É«Ê¦í IL4/IL13 ,¦PDUPILUMAB ,¦ýµLDUPILUMABµ²¼Òª¢°Æ§@¥Î,¤½¥q»{¬°¥¼¨ÓASLAN004Àø®ÄBETTER THAN DUPILUMAB ¼Ð·ÇÀøªk)
2.FB825:ÀR¯ßª`®g/1¤ë¤@°w(¦X¤@/LEO):5»õ¬üª÷ ---------(²Ä¤@¥NIgE§í¨î¾¯³Ý³ß·ç¼Ö ® á´¹ª`®g¾¯ 150 ²@§J ½Ã¸pµß¬Ì¿é¦r²Ä 000835 ¸¹ Xolair ¶·«öÅ髤ÎIgE°tÃÄ,¥Ø«e¬Oý³Ý³Ì«á¤@½u, AD Á{§É没¦¨¥\) ¥Ñ±ÂÅvª÷®t 5.3»õ¬ü¤¸,¶È°ê»Ú¦æ±¡1/2~1/3,
www1.ndmctsgh.edu.tw/pharm/pic/medinsert/005XOL01.pdf
3. DUPILUMAB¡]¦A¥Í¤¸»sÃĤ½¥q/Dermire: 14»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%. -----(µL¸ê®Æ)
4. Dermire ¡¦s Lebrikizumab³QLily¦¬ÁÊ,¤T´Ápass¡^¡G11»õ¬ü¤¸ --------(«Ê¦í IL13,¤Î³¡¥÷IL4,Àø®Ä¬ùDUPILUMAB75%) 5. CBP-201 2b ------(MOA¦Pdupilumab,¦³±M§Q ·ÀI,¤¤°êªºADR¥i¯à³Q¬ü°êµý´Á·|¤U¥«)
6. Adtralza® (tralokinumab) ¤µ¦~6¤ë¤v¨ú±o¼Ú¬w+^Ãĵý¡]LEO ªí¥Ü¬ü°êÃĵý¹wp©ú¦~ªì¨ú±o¡^ -----(«Ê¦í IL13,¤Î³¡¥÷IL4,Àø®Ä¬ùDUPILUMAB50%)
7. IVL-094¡AIL22§í¨î¾¯¡AªvÀø¤¤-««×AD -----(没¦¨¥\,没¦³·sÁ{§É«Ü¦h¦~) 8. KHK4083:¤é¥»ÄQÅï±ÂÅv¦w¶iKHK4083 -----(¤£¦PMOA,¤G´Á¥§¡°´T¶È50%,¤£¬ODUPILUMAB¹ï¤â)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2021/12/21 ¤U¤È 04:43:36
²Ä 4998 ½g¦^À³
|
1.ASLN004(2b):¥Ö¤Uª`®g/¤@¤ë¤@°w 2.FB825:ÀR¯ßª`®g/1¤ë¤@°w(¦X¤@/LEO):5»õ¬üª÷ 3. DUPILUMAB¡]¦A¥Í¤¸»sÃĤ½¥q/Dermire: 14»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%. 4.Lebrikizumab(³QLily¦¬ÁÊ,¤T´Ápass¡^¡G11»õ¬ü¤¸ 5. CBP-201 2b 6. Adtralza® (tralokinumab) ¤µ¦~6¤ë¤v¨ú±o¼Ú¬w+^Ãĵý¡]LEO ªí¥Ü¬ü°êÃĵý¹wp©ú¦~ªì¨ú±o¡^ 7. IVL-094¡AIL22§í¨î¾¯¡AªvÀø¤¤-««×AD 8. KHK4083:¤é¥»ÄQÅï±ÂÅv¦w¶iKHK4083
1.³o»ò¦hÃÄ¡AASLN004 ¦p¦ó²æ¿o¦Ó¥X? 2. ³o»ò¦hÃÄ¡A¨CÓÃıÂÅv¶O³£¬O5-20»õ¬üª÷¡A¨ì©³³o¨ÇÃļt¡An«ç»ò©w¦ì¥L̶RªºÃÄ¡A¤~¯àÁȱo¦^±o
¤£ª¾¹D¦U¦ì¥ý¶i¦³¦ó¬Ýªk¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/12/21 ¤U¤È 02:47:18
²Ä 4997 ½g¦^À³
|
Dupilumab ¤µ¦~¦ôÀ禬62»õ¬ü¤¸¡C
2022¦~¦ô¾P80»õ¬ü¤¸ 2023¦~¦ô¾P100»õ¬ü¤¸¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/12/21 ¤U¤È 02:10:38
²Ä 4996 ½g¦^À³
|
2022¦~¥þ²y¤Q¤jºZ¾PÃĪ« Dupilumab±N·|À½¶i«e¤Q¤j ©¡®É¼Ðº]Àø®Äµ¥³£Ä¹¹LDupilumabªºASLAN004 ±N·|¤Þ°_¨ÖÁÊÃļtªºÁ»¿Ì. (2022¦~11¤ë±q¦U¤jÃļtQ3°]³ø´Nª¾¹D¥þ²y¤Q¤jºZ¾PÃĪ«±Æ¦W¤F) ¨È·à±d®É¶¡ÂIºâ±oèè¦n.¼F®`. 1.2022¦~Q3´Á¤¤³ø§i 2.2022¦~11¤ë¤½¥¬2022¦~¥þ²y¤Q¤jºZ¾PÃĪ«¹w´ú(Dupilumab±N¥X¦C) 3.2022¦~Q4±ÂÅv 4.2022¦~©³ASLAN004¥¿¦V¸Ñª¼ 5.µ¥³Q¦¬ÁÊ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/12/19 ¤W¤È 11:04:38
²Ä 4995 ½g¦^À³
|
Ó®×¥«³õ¤ÀªR ¤G -----§ó¥¿-----BÃÄ 118,000¬ü¤¸/¦~ 1. AÃÄ 48,000¬ü¤¸/¦~(·R´þ¯f³Ì«á¤@½u¡A¨C¤é¤G°w¡A3000~4000¤Hªº¬ü°ê¥«Ô·,¬ù2008¦~¬ü°ê¥«Ô·¤W¥«,²Ä¤@Ó¤ë600¤H³B¤èñ) 2. BÃÄ 118,000¬ü¤¸/¦~(·R´þ¯f³Ì«á¤@½u¡A¨C¤G¶g¤@°w¡A2018¦~4¤ë¬ü°ê¥«Ô·¤W¥«,²Ä¤@Ó¤ë100¤H³B¤èñ¡C) ³Ì«á¤@½u¬ü°ê¥«³õ12,000¤H,¥Ø¼Ð«È¤á6,000¤H.(¨ú±oFDA ,BTD)
¥Ø«eBÃľP°â¥¼¨£°_¦â(2020¦~¦~¾P,¥¼¶W1»õ¬ü¤¸,¦ô¥¼¾P¶W1000¤H³B¤èñ/¦~) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/12/19 ¤W¤È 10:51:22
²Ä 4994 ½g¦^À³
|
Ó®×¥«³õ¤ÀªR ¤G. 1. AÃÄ 48,000¬ü¤¸/¦~(·R´þ¯f³Ì«á¤@½u¡A¨C¤é¤G°w¡A3000~4000¤Hªº¬ü°ê¥«Ô·,¬ù2008¦~¬ü°ê¥«Ô·¤W¥«,²Ä¤@Ó¤ë600¤H³B¤èñ) 2. BÃÄ 11,800¬ü¤¸/¦~(·R´þ¯f³Ì«á¤@½u¡A¨C¤G¶g¤@°w¡A2018¦~4¤ë¬ü°ê¥«Ô·¤W¥«,²Ä¤@Ó¤ë100¤H³B¤èñ¡C) ³Ì«á¤@½u¬ü°ê¥«³õ12,000¤H,¥Ø¼Ð«È¤á6000O.(¨ú±oFDA BTD)
¥Ø«eBÃľP°â¥¼¨£°_¦â(2020¦~¦~¾P,¥¼¶W1»õ¬ü¤¸) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/12/19 ¤W¤È 08:56:16
²Ä 4993 ½g¦^À³
|
Ó®×¥«³õ¤ÀªR 1.Hx 600¬ü¤¸/¦~(¬ü°êªº´À¥N¥ÎÃÄ¡A¨C¤é¤fªA¡A160,000¤Hªº¬ü°ê¥«Ô·) 2.Px 48,000¬ü¤¸/¦~(¬ü°êªº´À¥N¥ÎÃÄ¡A¨C¶g¤@°w¡A10000¦h¤H¨Ï¥Î¤¤¡C) 3.Bx 180,000¬ü¤¸/¦~(¥Ø«e¦û54%¥«³õ¬ü°êMedicare¤£¦P·N¥I) ¡A11¤ëFDA®Öã¤W¥«)
healthunlocked.com/mpnvoice/posts/147304091/medicare-denies-besremi-coverage-the-saga-begins
¬ü°ê°ê®a¤Î¨p¤H«OÀI³W©w«K©yªºÃÄ¥ý¥Î¡C
¦bµL¥ô¦ó¸T¤î¨Ï¥Î©R¥O«e¡A´À¥N¥ÎÃĤ£·|°±¡C
¥H¤W¦U¦ì§ë¸êªÌ¡An¦Û¤v¥hµû¦ô¥«³õ渗³z²v¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/12/18 ¤W¤È 06:04:45
²Ä 4992 ½g¦^À³
|
2020¦~¤¸¤ëªì«Å¨ÖÁÊ¡A §¨Ó¥Î8Ó¤ë©MDermire¤½¥q §¹¦¨¨ÖÁÊ¡A·í®É¥«³õªº»{ª¾°ò¦¬ODupilumab ³Ì°ª¾P°â50»õ¬ü¤¸(2019¦~¹ê»Ú¦~¾P21»õ¬ü) ¡K¡KREGN ·s¥ôCEO ¦b2019¦~12¤ë«Å¥¬¡ADupilumab ·s¥Ø¼Ð³Ì°ª¾P°â100»õ¼Ú¤¸(110»õ¬ü¤¸)¡C
AD¦û约55% 50¡Ñ55%=27.5»õ¬ü¤¸¡K¡K2019¦~Dupilumab ³Ì°ª¾P°â预´Á
§¨Ó¥H11»õ¬ü¤¸¨ÖÁÊDermire 11»õ¬ü¤¸+¤ä¥I¤W´åù¤óROCHE ¥Ø«e¬Ý§¨Ó¬O¤j赢®a¡C
Yµ¥2¦~¡ALebrekizumab AD¤T´Á°µ§¹ªº¤µ¤Ñ¡A¦ôp
11¡Ñ(110/50)¡Ñ2=48»õ¤è¯à¶R¤UDermire(lebrikizumab)
¡G¤Ñ©R10141925 µoªí®É¶¡:2021/12/17 ¤U¤È 02:42:15²Ä 4990 ½g¦^À³ Lebrikizumab 2017¦~ ¤w°µ§¹ý³Ý¤T´Á¥¢±Ñ. COPD ¤T´Á¥¢±Ñ. (tralokinumab ý³Ý¤T´Á¦P¼Ë¥¢±Ñ.¦ý¤µ¦~AD¤wÀò¼Ú¬wÃĵý)
www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M ý³Ý¤T´Á³ø§i¦p¤W.
2017¦~ù¤óROCHE¤~±ÂÅvDERMIRE ¤½¥q¥h°µ¤G´ÁAD.
2017/08/08 (2019/10 ¤T´ÁÁ{§É¶}©l) Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv«eª÷8000¸U¬ü¤¸¡A2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%. Áô§t28»õ¬ü¤¸³Ì°ª¾P°âÃB.
©Ò¥HLebrikizumab¥u¥i¥H¥h·mDupilumab AD ¬ù66»õ¥«³õ.
16¶g¤T´Á¤w¹LÃö,¦ý¥¼¤½§G¼Æ¾Ú. ¥t¦³©µ¦ù¨ì52¶gªº¤T´Á©|¦bÁ{§É¤¤.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/12/17 ¤U¤È 03:37:05
²Ä 4991 ½g¦^À³
|
www-marketbeat-com.cdn.ampproject.org/v/s/www.marketbeat.com/instant-alerts/nasdaq-asln-options-data-report-2021-12-2-3/amp/?amp_js_v=a6&_gsa=1&usqp=mq331AQKKAFQArABIIACAw%3D%3D#aoh=16397263435641&referrer=https%3A%2F%2Fwww.google.com&_tf=%E4%BE%86%E6%BA%90%EF%BC%9A%251%24s&share=https%3A%2F%2Fwww.marketbeat.com%2Finstant-alerts%2Fnasdaq-asln-options-data-report-2021-12-2-3%2F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/12/17 ¤U¤È 02:42:15
²Ä 4990 ½g¦^À³
|
Lebrikizumab 2017¦~ ¤w°µ§¹ý³Ý¤T´Á¥¢±Ñ. COPD ¤T´Á¥¢±Ñ. (tralokinumab ý³Ý¤T´Á¦P¼Ë¥¢±Ñ.¦ý¤µ¦~AD¤wÀò¼Ú¬wÃĵý)
www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M ý³Ý¤T´Á³ø§i¦p¤W.
2017¦~ù¤óROCHE¤~±ÂÅvDERMIRE ¤½¥q¥h°µ¤G´ÁAD.
2017/08/08 (2019/10 ¤T´ÁÁ{§É¶}©l) Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv«eª÷8000¸U¬ü¤¸¡A2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%. Áô§t28»õ¬ü¤¸³Ì°ª¾P°âÃB.
©Ò¥HLebrikizumab¥u¥i¥H¥h·mDupilumab AD ¬ù66»õ¥«³õ.
16¶g¤T´Á¤w¹LÃö,¦ý¥¼¤½§G¼Æ¾Ú. ¥t¦³©µ¦ù¨ì52¶gªº¤T´Á©|¦bÁ{§É¤¤.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/12/17 ¤U¤È 02:05:09
²Ä 4989 ½g¦^À³
|
ÅÞ¿è«ä¦ÒÃD¡G 1.Lebrikizumab 3´ÁÁ{§É¤~è§@3Ó¤ë´N³QLily¦¬ÁÊ¡C a.²§¦ì©Ê¥Ö½§ª¢¬O¤@ºØ¼vÅT¬ü°ê2,400¸U¤H(¥þ²y¶W¹L2»õ)ªººC©Êª¢¯g b.³Ì°ª¾P°âÃB¥i¹F 120»õ¬ü¤¸(Dupilumab)
2.Etrasimod(Arena Pharmaceuticals)3´ÁÁ{§É³Ñ3Ó¤ë¸Ñª¼´N³Q½÷·ç¦¬ÁÊ¡C a.¼ìºÅ©Êµ²¸zª¢¬O¤@ºØ¼vÅT¬ü°ê300¸U¤HªººC©Êª¢Äp©Ê¸z¯f b.³Ì°ª¾P°âÃB¥i¹F 25»õ¬ü¤¸ c.ªvÀø®ÄªG±N¤ñ Bristol Myers Squibb(¦Ê®É¬ü¬I¶QÄ_)ÃļtºX¤Uªº Zeposia§ó¦³®Ä
¦]¬°²§¦ì©Ê¥Ö½§ª¢(¬ü°ê2,400¸U¤H)¤ñ¼ìºÅ©Êµ²¸zª¢(¬ü°ê300¸U¤H)¼vÅT¤H¼Æ§ó¼s¡C ÁöµMEtrasimodÃĮĤñZeposia ¦n¡A¦ý³Ì°ª¾P°âÃB¶È¹F 25»õ¬ü¤¸¡A½÷·ç¥i¥Hµ¥Etrasimod§Ö3´Á¸Ñª¼¦A¦¬ÁÊ(¦]¬°¤£¤j·|¦³¤H·m¦¬ÁÊ)¡C ¥i¬O¡ALebrikizumab¦³³Ì°ª¾P°âÃB¹F 120»õ¬ü¤¸ªº¥«³õ¡AÁöµM¨ä2bÁ{§É¼Æ¾Ú¨SDupilumabº}«G¡A¦ý«o¤]¦³¦Û¤vªº¥«³õ¡A¤~è§@3´Á¡A´N³QLily»°ºò¦¬ÁÊ¡C ================================================================================================ ASLAN004¦³³Ì°ª¾P°âÃB¹F 120»õ¬ü¤¸ªº¥«³õ(ÁÙ·|½Õ°ª)¡A¥un©e°UIQVIA Biotech §â2bÁ{§É¼Æ¾Ú§@º}«GÂI¡AÃĮĤj©ó(©Îµ¥©ó) Dupilumab¡A¤£¥Î§@3´ÁÁ{§É(©Î«Å¥¬¦ó®É§@3´Á)¡A´N·|³Q¦¬ÁʤF(¦]¬°¾P°âÃB¤j¨ìÅýÃļt²´¬õ)(·Q¨ÖªºÃÄ°Óµ¥¤£¤F¨È·à±d¶}©l§@3´Á¡A¦]¬°2b¸Ñª¼¼Æ¾Ú´N¥i·í§@¦¬Áʨ̾ڤF)¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/12/16 ¤U¤È 03:09:24
²Ä 4988 ½g¦^À³
|
¦ôp
¶}59Ó¤¤¤ß, ¨C¤¤¤ß¦¬5¤H.¦Xp295¤H,
¿D¬w6+¯Ã/·s¥[©Y 8Ó¤¤¤ß,²Ä¤@ªi¦¬®×.
©ú¦~ªì¶}¬ü°ê,¼Ú¬w¦¬®×¤¤¤ß.
2022¦~ 4¤ë¤¤¦¬®×§¹¦¨ + 4Ó¤ëªvÀø+3Ó¤ë°lÂÜ+1Ó¤ë¸Ñª¼·Ç³Æ 2022¦~12¤ë¤¤¸Ñª¼. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/12/16 ¤U¤È 02:26:13
²Ä 4987 ½g¦^À³
|
Á׶}¬Ì±¡ÄY®mªº°ê®a 2bÁ{§É¸ÕÅç¿ï:
¿D¬w ¯Ã¦èÄõ ·s¥[©Y
¼F®`¼F®` |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/12/16 ¤W¤È 11:46:33
²Ä 4986 ½g¦^À³
|
·PÁ¤ѩR¤j¤j «¾ã¦p¤U
¬ü°ê¥Í§Þ¤½¥q Arena Pharmaceuticals(ÁÙ¨S®³¨ìÃÄÃÒ) ªÑ¥»¡G67,000,000ªÑ ¼ìºÅ©Êµ²¸zª¢¬O¤@ºØ¼vÅT¬ü°ê300¸U¤HªººC©Êª¢Äp©Ê¸z¯f ³Ì°ª¾P°âÃB¥i¹F 25»õ¬ü¤¸ Etrasimod ¥¿³B©ó«á´Áªº¬ã¨s¶¥¬q¡AªvÀø®ÄªG±N¤ñ Bristol Myers Squibb(BMY-US) (¦Ê®É¬ü¬I¶QÄ_)ÃļtºX¤Uªº Zeposia §ó¦³®Ä ½÷·ç¦P·N¥H 67»õ¬ü¤¸¦¬ÁÊ¡A´«ºâ¨CªÑ¦¬Áʳø»ù¬° 100 ¬ü¤¸
·s¥[©Y¥Í§Þ¤½¥q ASLAN Pharmaceuticals(ÁÙ¨S®³¨ìÃÄÃÒ) ªÑ¥»¡G69,663,404ªÑ ²§¦ì©Ê¥Ö½§ª¢¬O¤@ºØ¼vÅT¬ü°ê2,400¸U¤H(¥þ²y¶W¹L2»õ)ªººC©Êª¢¯g ³Ì°ª¾P°âÃB¥i¹F 120»õ¬ü¤¸(Dupilumab) ASLAN004¥¿³B©ó2bÁ{§Éªº¬ã¨s¶¥¬q¡AªvÀø®ÄªG±N¤ñÁÉ¿ÕµáÃļtºX¤UªºDupilumab§ó¦³®Ä (ASLAN004 , ±NÀu©óDupilumab ¤W¥«¼Ð·ÇÀøªk ,2¶g¤@°w300mg~~ASLN¤½¥q²¤¶)
clinicaltrials.gov/ct2/show/results/NCT01859988?term=NCT01859988&draw=2&rank=1 Dupilumab AD,2b ªºµ²ªG,¦p¤W
XXX¦P·N¥H 000»õ¬ü¤¸¦¬ÁÊ¡A´«ºâ¨CªÑ¦¬Áʳø»ù¬°???¬ü¤¸ ------------------------------------------------------------------------------------------------------------------------------------ ¨È·à±d§@3´Á®É³Q¨ÖÁÊ»ù®æ67»õ¬ü¤¸°_¸õ(¥¼ºâASLAN003¡K¡Kµ¥)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/12/16 ¤W¤È 11:11:15
²Ä 4985 ½g¦^À³
|
clinicaltrials.gov/ct2/show/results/NCT01859988?term=NCT01859988&draw=2&rank=1
Dupilumab AD,2b ªºµ²ªG,¦p¤W
ASLAN004 , ±NÀu©óDupilumab ¤W¥«¼Ð·ÇÀøªk ,2 ¶g¤@°w300mg,(ASLN¤½¥q²¤¶)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/12/16 ¤W¤È 10:30:58
²Ä 4984 ½g¦^À³
|
ARNA¥«È20´X»õ¬ü¤¸¥«³õªºÃÄ¡A¤T¥|¦~«e ¤w¸g20¥H¤W¤@¸ô©¹¤W¡A¤jº¦¤p¦^ª½¨ì¨ÖÁÊ ¤]´N¬O»¡°µ¤@¡A¤G´Á´N¶}©lº¦¤F¡A¦P¼Ë ©M¦Ñ·à¤@¼Ë¥Rº¡¥¼ª¾ªº·ÀI ¬O¤£¬O¦³¶Â¤â¡A¤£¥i¦Ò¡A¥uª¾¹DªÑ»ù©e©}¤F¡C ¬JµM¤£¦X²z¦ÛµM·|¦^Âk¥¿±` |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 1601 ~ 1700 «h¦^ÂÐ >> |